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ABSTRACT 
AG to A transition at position -76 in the promoter region 
of the apoAI gene was previously identified, and the A-76 
has been shown to be associated with high apoAI levels. The 
functional significance of the point mutation was assessed 
by analysing the DNA-protein binding and promoter activities 
of the different alleles. This data would suggest that the 
point mutation alters the function of the apoAI promoter as 
gel retention assays revealed that the G fragment (-140 to 
+10) formed an extra DNA-protein complex compared to the A 
fragment {-140 to +10). 
Concurrent with the altered DNA-protein interaction between 
the G and the A fragments, the transcriptional activities of 
the apoAI gene were found to also be altered. CAT assays 
have indicated a 1.91 fold increase in promoter activity of 
the A fragment as compared to the G fragment (-256 to +397). 
The difference in promoter activity was, however, highly 
dependent on the particular fragment used, as no difference 
was observed between the alleles when a fragment {-256 to 
+68) was used. In this study elements were identified in the 
region +68 to +397 that causes a reduction in the promoter 
activity of the G allele by 3.6 fold, whilst reducing the A 
allele activity by 2 fold. This data would suggest that the 
point mutation functionally alters the apoAI promoter 
activity via its interaction with other sequences especially 
in the region +68 to +397. 
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ABBREVIATIONS 
AID1 - apoAI footprint D protein 1 
AID2 - apoAI footprint D protein 2 
ARP-1 - apoAI related protein - 1 
ATP - adenosine triphosphate 
BSA - bovine serum albumin 
CAAT - CAT box 
CAT - chloramphenicol acetyltransferase 
CETP - cholesterol ester transfer protein 
CHO - coronary heart disease 
CIP - calf intestinal phosphatase 
CIPPED - the action of dephosphorylating 
CpG - a region of DNA consisting of mainly cytosine and 
guanosine 
DTT - dithiothreitol 
EDTA - ethylenediaminetetra-acetic acid 
EtBr - Ethidium Bromide 
µg - mirogram 
µl - microlitre 
HBS - hepes buffered saline 
HDL - high density lipoproteins 
HDL-C - HDL-cholesterol 
Hepes - (N-(2-Hydroxyethyl}piperazine-N'-(2-ethanesulfonic 
acid)) 
HP - hepatic lipase 
IDL - intermediate density lipoprotein 
kb - kilobase pairs 
kDa - kilodalton 
LCAT - lecithin cholesterol acyl transferase 
LDL - low density lipoproteins 
LDL-C - LDL-cholesterol 
LDL-R - low density lipoprotein receptor 
LPL - lipoprotein lipase 
M - molar 
mM - mili molar 
nm - nano metres 
NTP - triphosphate nucleotide 
vi 
OD - optical density 
ONPG - o-nitrophenyl-B-D-galactopyranoside 
PBS - phosphate buffered saline 
PCV - packed cell volume 
Pipes - piperazine-N,N'-bis(2-ethanesulfonic acid) 
PMSF - phenylmethylsulfonyl fluoride 
RARE - retinoic acid-responsive element 
Rf - relative mobility to front 
RFLP - restriction fragment length polymorphism 
RXRa - retinoic acid receptor 
sos - sodium dodecyl sulphate 
TATA - TATA box 
TBE - tris, boric acid, ethylenediaminetetra-acetic acid 
TE - tris, boric acid 
TLC - thin layer chromatography 
TNE - tris, NaCl (sodium chloride), EDTA 
VLDL - very low density lipoproteins 
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Cholesterol is essential for maintaining the structure of 
biological membranes and is a precursor for steroid hormon
es 
and other molecules (review 1,2). Cholesterol is absorbed 
from a dietary source in the intestine or is synthesized, 
de 
novo, in the cells. Cholesterol, a hydrophobic molecule does 
not readily dissolve in blood, and therefore, it must be 
transported in the circulation as part of a lipoprotein 
particle which is soluble in the plasma. Lipoprotein 
paticles consist of a monolayer of phospholipids and are 
associated with apolipoproteins. Chylomicrons, very low 
density lipoproteins (VLDL), intermediate density 
lipoprotein {IDL), low density lipoproteins (LDL) and high
 
density lipoproteins (HDL) are the lipoproteins involved i
n 
the transport of cholesterol and triglyceride within the 
plasma (figure 1). 
1 
2 
A. The transport of dietary cholesterol and triglyceride to 
the liver: 
Dietary triglyceride and cholesterol are packaged into 
chylomicrons in the intestine and secreted into the 
lymphatic system. In the blood the chylomicrons are 
remodelled via the hydrolysis of triglyceride by lipoprotein 
lipase (LPL) and also by the exchange of apolipoproteins 
with HDL. This maturation process converts the chylomicrons 
to chylomicron remnants which deliver the cholesterol and 
the triglerceride to the liver via a specific chylomicron 
remnant receptor, postulated to be the LDL-R related protein 
(3) (figure 1 for details). 
B. Transport of cholesterol and triglyceride from the liver 
to the peripheral cells: 
The major vehicle for the movement of triglyceride and 
cholesterol from the liver to peripheral cells is the VLDL. 
As in the chylomicrons, the triglyceride in the VLDL is 
hydrolysed by LPL. The triglyceride is also exchanged for 
cholesterol esters from HDL via the cholesterol ester 
transfer protein (CETP) (4,5). The remodelling processes 
converts VLDL to intermediate density lipoprotein (IDL). IDL 
can either be endocytosed by the LDL-R via the apoE on its 
surface or the triglyceride in the particle can be lipolysed 
by the LPL or hepatic lipase (HP) (4,5,6). This converts IDL 
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Dietary triglyceride and cholesterol are packaged into 
chylomicrons in the intestine and secreted into the 
lymphatic system. In the blood the chylomicrons are 
remodelled via the hydrolysis of triglyceride by lipoprote
in 
lipase (LPL) and also by the exchange of apolipoproteins 
with HDL. This maturation process converts the chylomicron
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to chylomicron remnants which deliver the cholesterol and 
the triglyceride to the liver via a specific chylomicron 
remnant receptor, postulated to be the LDL-R related prote
in 
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B. Transport of cholesterol and triglyceride from the live
r 
to the peripheral cells: 
The major vehicle for the movement of triglyceride and 
cholesterol from the liver to peripheral cells is the VLDL
. 
As in the chylomicrons, the triglyceride in the VLDL is 
hydrolysed by LPL. The triglyceride is also exchanged for 
cholesterol esters from HDL via the cholesterol ester 
transfer protein (CETP} (4,5). The remodelling processes 
converts VLDL to intermediate density lipoprotein (IDL}. I
DL 
can either be endocytosed by the LDL-R via the apoE on its
 
surface or the triglyceride in the particle can be lipolys
ed 
by the LPL or hepatic lipase (HP) (4,5,6). This converts I
DL 
to LDL. The LDL is delivered to peripheral cells via the 
LDL-R. The single apolipoprotein B associated with the LDL 
particle binds to the LDL-R, which mediates endocytosis of 
LDL (figure 1). 
3 
C. Transport of cholesterol from the peripheral cells to the 
liver: 
The removal of excess free cholesterol from peripheral cells 
is carried out by HDL. The free cholesterol associated with 
the HDL, is esterified and transported to the liver where it 
is either reutilized or converted to bile acids and is 
excreted (review 7). Free cholesterol from VLDL and IDL is 
also packaged in the phospholipid monolayer of HDL and 
esterified by the enzyme lecithin cholesterol acyl 
transferase (LCAT) to cholesterol ester (figure 1). The 
process by which the cholesterol is transported from 
peripheral cells to the liver, is refered to as reverse 
















































































































































































































































Figure 1: Schematic diagram illustrating lipoprotein 
interactions and the enzymes involved in cholesterol 
homeostasis. 
The letters in the diagram represent the following: 
BlOO - apoBlOO; E - apoE; C - apoc; AI - apoAI; 
AII - apoAII; B48 - apoB48; AIV - apoAIV; FC - free 
cholesterol; PL - phospholipid; CE - cholesterol ester; 
TG - triglyceride; LPL - lipoprotein lipase; HL - hepatic 
lipase; LCAT - lecithin cholesterol acyltransferase; 
CETP - cholesterol ester transfer protein; 
cells - peripheral cells; VLDL - very low density 
lipoprotein; IDL - interrnediat density lipoprotein; 
LDL - low density lipoprotein; LDL-R - LDL-receptor; 
HDL - high density lipoprotein; HDL2 and HDL3 - subclasses 
of HDL; CM - chylornicron; CMR - chylornicron remnants; 
CMR-R - CMR-receptor. 
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1.2 APOAI, HDL AND CORONARY HEART DISEASE: 
Cholesterol levels have been indicated as a ris
k factor in 
coronary heart disease (9,10,11). Results obta
ined from the 
Framingham Heart Study determined that HDL-C (
HDL-
cholesterol) was a potent predictor of coronar
y heart 
disease (CHD) death in both sexes (11). HDL le
vels are 
inversely correlated with CHD and have been pro
posed to be a 
protective factor against CHD (9). Patients wi
th myocardial 
infarction have significant lower HDL2 and HDL3 
levels than 
normal individuals (12). HDL2 levels have been
 found to be a 
better predictive factor of HDL-C than HDL3 as
 there is a 
strong correlation between HDL-C and HDL2 conc
entrations, 
but not with HDL3 concentrations (13)
. ApoAI, being the 
major apolipoprotein associated with HDL, has 
been 
positively correlated with HDL levels (14). It
 has been 
shown that the apoAI levels can be used as a r
isk factor for 
myocardial infarction (12) and stroke (9) pati
ents. This 
relationship was observed in both males and in
 females (15). 
In transgenic mice the apoAI levels were also 
correlated to 
HDL-cholesterol levels (16,17,18). 
The protective nature of the apoAI and HDL lev
els was also 
shown by Rubin, et al. in transgenic mice (19)
. They 
integrated the human apoAI gene into the genom
e of a mouse 
strain that was normally susceptible to athero
sclerotic 
lesions at 14 to 18 weeks. Results obtained in
dicated that 
high human plasma apoAI and HDL concentrations
 inhibited 
early atherogenesis in these transgenic mice. 
6 
From these studies it has been concluded t
hat high HDL and 
apoAI levels appear to protect against the
 development of 
heart disease. It is, therefore important 
to understand the 
role of HDL and apoAI in reverse cholester
ol transport and 
also to determine how the apoAI gene is re
gulated. 
1.3 HDL AND REVERSE CHOLESTEROL TRANSPORT: 
Reverse cholesterol transport is important
 as extrahepatic 
cells cannot catabolize the cholesterol th
ey accumulate 
(review 2). 
A. The sequestration of free cholesterol f
rom the cells: 
The first step in reverse cholesterol tran
sport is the 
sequestration of free cholesterol from the
 cells by HDL. Two 
general questions about the uptake of free
 cholesterol by 
HDL exist: 
1. Does the HDL interact with the peripher
al cell via a 
receptor or not? 
There are many studies that suggest that a
n HDL-receptor 
(HDL-R) exists in various tissues (20,21,2
2,23). The reports 
also imply that apoAI is the ligand that i
s reponsible for 
the specificity of HDL binding to the HDL-
R. Both 
subfractions HDL3 and HDL2 were equ
ally able to efflux free 
7 
cholesterol from macrophages as they bound wit
h high 
affinity to a surface receptor (23). The recep
tor was 
investigated by Xu (21), who found that in rab
bit smooth 
muscle cells HDL3 bound specifical
ly and with high affinity 
to the cell surface. Xu also reported that apo
AI was the 
ligand for the receptor as non-radioactively-l
abelled apoAI 
competitively blocked radioactively-labelled H
DL3 from 
binding to the rabbit smooth muscle cells by 5
0%. HepG2 
cells (transformed human liver cells) were also
 reported to 
have a specific binding site for apoAI (20). A
 110 
kilodalton (kDa) membrane-associated glycoprot
ein, that 
avidly binds HDL was isolated and identified fr
om beef lung 
(24,25). It was determined that this glycoprot
ein was 
regulated by HDL and exibited specificity; whi
ch is typical 
of receptors. In summary, these studies have p
roposed that 
there is an HDL-R that has specificity and hig
h affinity for 
apoAI; also there are specific domains within 
the apoAI that 
are responsible for HDL binding to the HDL-R. 
More details 
about the apoAI-HDL-R interaction were investig
ated by 
Morrison and coworkers (22) who found that the
 carboxyl 
terminal of apoAI was responsible for the inte
raction with 
the HDL-R in rat liver plasma membranes. 
In contrast, other reports suggest that apoAI 
does not bind 
via an HDL receptor (26). HDL was reported to 
associate with 
the HepG2 cell via the apoAI's amphipathic alp
ha-helical 
repeats, as antibodies directed against the he
lical repeats 
inhibited the binding of the HDL by 9 to 15% (
27). This 
finding is not compatible with the existence o
f a receptor 
8 
as the apoAI has been proposed to associate with lipids 
through its ampiphathic domain (28). Mendel, et al. (29) 
have also reported that binding of the HDL is not mediated 
via a "classic" protein receptor, and that it is mediated 
via a set of very low molecular weight particles 
approximately lOkDa and 16kDa in size. 
2. How does the cholesterol move from the cell to the HDL? 
9 
Cholesterol has been proposed to be present in various pools 
in the cell {30,31) which are distinguished by their 
cholesterol to phospholipid ratio (32,33). Three different 
models have been proposed to explain the movement of 
cholesterol from cells to HDL, via the different pools 
within the cell. 
a. Removal of cholesterol via retroendocytosis: 
HDL retroendocytosis has been proposed as a model for 
aquisition of cholesterol from certain peripheral cells 
(34,35,36). Research done on HepG2 cells suggests that HDL 
binds via a receptor, is internalized and is resecreted by 
HepG2 cells {36). Along the retroendocytosis pathway HDL 
aquires cholesterol from internal cholesterol pools. In 
patients with Tangier's disease there is little or no 
detection of HDL in the circulation. This was reported to be 
due to faulty retroendocytosis of the HDL (34) i.e. the HDL 
was internalized by the cells, but was not resecreted. 
b. Removal of cholesterol via a second mes
senger system: 
This was proposed by Oram, et al. (37) who
 studied the 
acquisition of cholesterol from cholestero
l loaded 
fibroblasts. They proposed that the remova
l of cholesterol 
from intracellular pools required the bind
ing of HDL to the 
cholesterol loaded fibroblast surface via 
a receptor. This 
binding could then trigger a second messen
ger system that 
causes translocation of the intracellular 
cholesterol to the 
surface of the cell. However, Oram and cow
orkers have 
evidence that the actual removal of choles
terol from the 
cells does not require a specific interact
ion between HDL 
and the cell. The cholesterol probably bec
omes part of the 
plasma membrane cholesterol pool that is r
emoved via passive 
diffusion. 
c. Removal of cholesterol by passive diffu
sion: 
Cholesterol that is associated with the me
mbrane of the cell 
has been proposed to move passively from t
he membrane into 
the immediate aqueous phase, and from ther
e it is 
incorporated into a nearby HDL particle (3
8). Passive 
diffusion was found to depend on physical 
parameters of the 
lipoproteins e.g. apolipoprotein compositi
on, and different 
physical parameters were required by diffe
rent cell types. 
All of these results imply that the seque
stration of 
cholesterol from the peripheral cells to H
DL is a very 
dynamic process. All three models could be
 accommodated if 
one proposes that the cholesterol from dif
ferent pools and 
10 
cells are removed via different mechanisms
. However the 
subject of cholesterol removal from the ce
ll to HDL is 
complex and these opposing views still need
 to be resolved. 
B. The maturation and delivery of HDL to th
e liver: 
The maturation process of HDL involves the
 acquisition of 
free cholesterol and its esterification via
 the action of 
LCAT, for which apoAI acts as a cofactor (
39). This causes 
the conversion of nascent HDL to HDL3, and
 HDL3 to HDL2 
(Figure 1 for details). The triglyceride in
 the core of 
HDL2, that was exchanged from the VLDL for 
cholesterol ester 
by CETP can also be hydrolysed by hepatic 
lypase (HL) which 
then causes the formation of HDL3 from HDL2
. The HDL2 can be 
selectively taken up by the liver (40). 
Another class of HDL, HDL1 (HDLc) is only 
found when animals 
or humans are fed a high cholesterol diet 
(4). HDL1 consists 
of mainly apoAI and apoE, and can be taken
 up by the apoE 
and apoB,E receptors. 
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1.4 THE EVOLUTION OF THE APOAI GENE: 
The major apolipoprotein associated with HDL, a
poAI, is 
synthesized in the liver and the intestine as a
 28.3 
kilodalton protein (41). The apoAI gene is foun
d in a 
cluster with the apoCIII and apoAIV genes on th
e long arm of 
chromosome eleven (figure 2) {42,43). The evolu
tion of the 
apolipoproteins has been studied by several gro
ups, and is 
of interest since the basic functions and struc
tures of the 
apolipoproteins are similar. The results of sta
tistical 
analysis comparing sequences of the apolipopro
teins AI, AIV 
and E demonstrated that all three proteins are 
members of a 
dispersed gene family, and that these genes hav
e arisen from 
gene duplication of a common ancestral gene (4
4). In 
contrast, the similarities of the amino acid se
quence 
between apoAI and apoCIII indicated that these 
proteins are 
a result of convergent evolution instead of div
ergent 
evolution (45). The apoAI.CIII.AIV cluster in b
irds has 
diverged from the human apoAI.CIII.AIV cluster,
 as birds 
have different cis-acting elements {46). Althou
gh the 
different apolipoproteins have specific functio
ns, their 
respective genes have genetic regions that allo
w for 
coordinated control (discussed later). 
12 
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Figure 2: Schematic diagram of the apoAI.CIII.AIV gene 
cluster. 
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The boxes represent the coding region of the apoAI, apoCIII 
and apoAIV genes which are represented by AI, CIII, AIV 
respectively. The arrows indicate the direction of 
transcription and the shaded and non-shaded areas represent 
the exons and introns. 
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1.5 THE EXTERNAL INFLUENCES ON APOAI PRODUCTION: 
The consequences of external stimuli e.g. exercise, hormones 
and diet, on the production of apoAI are important factors 
to consider when advising a patient, that is susceptible to 
CHO, on how to reduce his/her risk of CHO. 
A. The Effect of Exercise: 
Exercise has been shown to alter plasma lipoprotein levels 
and reduce the risk of CHO. The plasma lipids and the 
lipoprotein levels have been shown to directly correlate to 
the number of kilometers run, as well as the duration of the 
exercise (47). The conclusions reached from this study was 
that an exercise threshold of 10km per week was needed to be 
maintained for at least nine months before a significant 
difference in plasma lipids and lipoprotein levels was 
detected between the control group and the exercising group, 
and that men who had initial high HDL-cholesterol (HDL-C) 
and low triglyceride levels had the "capability" to run more 
miles. At lower exercise levels, the fitness increased and 
the percentage body fat decreased before the HDL-C and the 
LDL-cholesterol (LDL-C) levels changed. 
These findings were supported by a similar study carried out 
over one year (48). There was a positive correlation between 
the distance exercised per week and the lipoprotein levels 
e.g. as the exercise load increased so did the plasma HDL 
increase, whilst LDL levels decreased. Wood, et al. (49) 
compared the methods of weight loss obtained b
y eating less 
and by exercising more. They found that the pla
sma 
lipoprotein profile was less atherogenic, in b
oth methods of 
weight loss, with an increase in HDL-C, HDL2 a
nd HDL3 
levels, and a decrease in the triglyceride lev
els. 
Tikkanen and callaborators (50) did a study co
mparing the 
percentage of slow-twitch muscle fibres and lip
oprotein 
levels. Results obtained positively correlated
 slow-twitch 
muscle with serum HDL-C and apoAI levels, and 
showed a 
negative correlation with triglyceride levels. 
These studies indicate that there is a trend to
wards altered 
lipoprotein profiles with increased exercise w
hich could 
cause a reduction in the risk of coronary hear
t disease. 
B. The Effect of Diet: 
Dietary intake of cholesterol and other relate
d molecules 
e.g. fats play an important role in the regula
tion of apoAI 
production. ApoAI mRNA levels in the liver hav
e been 
reported (51) to be significantly upregulated 
in male rats 
when they received a fat supplement of either 
coconut, corn 
or olive oil for 2 months compared to the cont
rols who 
recieved either chow diet or chow plus 0.1% ch
olesterol. 
Srivastava and callaborators (52) studied the 
regulation of 
apoAI in three inbred mice strains. ApoAI mRNA
 levels 
increased in all strains when they were fed a 
high fat diet. 
All had increased apoAI protein, except one st
rain which 
also had increased apoAI mRNA transcription le
vels. This 
15 
implies that in these strains of mice the high fat diet 
influenced the apoAI mRNA via different mechanisms e.g. an 
increase in mRNA transcription and/or an increase in mRNA 
stability. 
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Dietary cholesterol (0.1% of the diet), however, did not 
affect the mRNA levels in the male rats (51), or in the 
study with the three inbred mice strains (52). However, in 
response to 0.5% cholesterol added to the diet, one strain 
showed increased apoAI protein synthesis and another strain 
had decreased plasma apoAI levels. These results suggest 
that a high cholesterol diet exerts its affect post-
transcriptionally as the mRNA and the transcription levels 
were unaffected, and that the effects differ between 
strains. 
Patsch, et al. (53) proposed that HDL concentrations are 
largely determined by postprandial plasma triglyceride 
concentrations. In Cebus monkeys (54) increased dietary 
triglycerides increased the hepatic apoAI (and apoB) mRNA 
levels. 
The response to dietary intake depends on the species of 
mammal, as even in different mice strains, the effect of the 
diet was different. The regulation of apoAI production seems 
to be at different levels depending on the different dietary 
constituents. 
c. The Effect of Hormones: 
Hormonal regulation is applied to many pathway
s in a cell, 
and HDL and apoAI levels are no exception. The
 level of 
plasma HDL-cholesterol is influenced by the le
vel of sex 
hormones. Estradiol treatment has differential
 effects 
depending on the dose administered. In post-me
nopausal 
women, estrogen raised the plasma HDL concentr
ation (55) and 
in castrated baboons there was an increase in 
apoAI 
synthesis (56). A similar increase of apoAI sy
nthesis and 
mRNA levels was observed in castrated inbred m
ice (57) when 
they were administered low doses of estradiol. 
In constrast, 
high doses (0.16µg/g/day) decreased apoAI mRNA
 levels and 
apoAI synthesis (57). From these studies it wo
uld appear 
that apoAI synthesis is increased by estradiol
. This, 
however, appears to be dependent on the levels
 administered. 
When estrogen and progesterone was administere
d to baboons 
it was found that there was an increase in apo
AI content of 
the HDL particle (56). The effect of administe
red 
testosterone (lmg/g/day) was determined in cas
trated female 
inbred mice and it was found that apoAI transla
tion, liver 
polysomal mRNA levels and apoAI synthesis incr
eased (57). 
Sex hormones appear to alter apoAI production, 
but the 
mechanisms by which this takes place must stil
l be 
clarified. 
Thyroid hormone administered to hypothyroid mi
ce caused an 
increase in apoAI gene expression. Interesting
ly, if the 
thyroid hormone dose was prolonged in the hypo
thyroid mice, 
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the mRNA level increased until a thresh
old level was reached 
(58). At this stage the mRNA concentrat
ion probably triggers 
a negative feedback mechanism that inh
ibits the production 
of the apoAI mRNA, and thus a constant 
raised mRNA level is 
maintained as long as the thyroid hormo
ne dose is continued. 
Davidson and coworkers (59} showed tha
t the thyroid hormone 
regulated the apoAI, apoAIV and apoB ge
nes independently and 
in a tissue specific manner. 
1.6 CONTROL OF THE APOAI GENE EXPRESSIO
N: 
Transcription is regulated by specific 
nuclear proteins that 
interact with the promoter region of ge
nes in a sequence 
specific manner. These proteins bind to
 the DNA and interact 
concordinantly to allow transcription o
f the gene to 
precede. The normal TATA and CAAT boxes
 necessary for 
transcription are present in the apoAI 
promoter, as well as 
other protein binding sites which allow
 for positive and 
negative control of the apoAI gene acco
rding to the external 
stimuli (60,61,62,63). 
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A. Tissue Specific Expression of the apoAI 
gene: 
The apoAI gene is expressed mainly in the 
liver and 
intestine of most mammals {41). The regula
tion of the apoAI 
expression is different in mammalian liver
 and intestine. 
The region -256 to -41 upstream of the sta
rt site {+l) of 
the apoAI gene was found to be sufficient 
for expression in 
HepG2 cells (transformed liver cells) and 
the region -2052 
to -192 was sufficient for Caco2 cell expr
ession 
(transformed intestinal cells) (64). In co
ntrast to cultured 
cells it was found that although -256 to -4
1 was sufficient 
for apoAI expression in the liver of transg
enic mice, the 
region -2052 to -192 was not enough for in
testinal 
expression in transgenic mice {16). 
DNA constructs containing deletions of the
 5' region of the 
apoAI promoter were transfected into apoAI
-producing and 
non-apoAI-producing cells in a tissue cultu
re system {65). 
Regions -1021 to -691; -487 to -413; and -2
50 to -199 (each 
in a separate construct) were found to be n
ecessary for 
maximum expression in both apoAI-producing
 (HepG2 cells) and 
non-apoAI-producing (Hutu 80 cells) cell li
nes. The same 
analysis was done with deletion mutants of
 the regions -2067 
to -1476; and -199 to -80 in separate cons
tructs, and the 
results indicated that these deletion regio
ns contain 
sequences required for tissue specific rep
ression of the 
apoAI expression in non-apoAI-producing ce
lls (65). 
19 
It would appear, therefore, that there 
are regions in the 
promoter of the apoAI gene that are req
uired for expression 
in apoAI-producing cells and for the in
hibition of 
expression in non-apoAI-producing cells
. 
B. Methylation of the apoAI gene: 
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Tissue specific DNA-protein interaction
s are probably not 
the only mechanism for determining tiss
ue specificity. 
Tissue specificity could also be regula
ted by different 
methylation patterns as the apoAI gene 
is hypomethylated in 
expressing tissues (66,67,68,69). 
Methylation of the apoAI gene occurs in
 three stages (68). 
In the oocyte, two sites in the 5
1 end of the mouse apoAI 
gene are unmethylated, but methylated i
n the sperm cell. A 
CpG island is, however, unmethylated in
 both the oocyte and 
the sperm cells. The methylation patter
n changes at the 
early embryo stage where all the methy
lated sites are 
demethylated. Then at the gastrulation 
stage the non-CpG 
islands are methylated followed by a gr
adual demethylation 
at specific sites in tissues that expre
ss the apoAI gene. It 
is postulated that tissue-specific met
hylation patterns 
proceed tissue-specific expression (67
). The DNA-protein 
interactions that determine tissue-spe
cificity are thought 
to be the initial determinants of tissu
e-specicifity, and 
thereafter the genes that are not being
 expressed are 
thought to be methylated to maintain ti
ssue-specificity. 
c. DNA-Protein Interactions Regulating Transcription: 
The region -256 to +17 in the apoAI promoter ha
s been 
extensively researched by a number of groups an
d DNAseI 
protection sites have been reported (60,61,62) 
within this 
region. 
Widom and coworkers (60) determined that the DN
A region -222 
to -110 was necessary and sufficient for HepG2 
cell line 
expression in in vivo transfection studies. They id
entified 
three protein binding sites, sites 1, 2 and 3 
(figure 3) 
within this -220 to -110 region. Site directed 
mutagenesis 
studies indicated that a minimum of any two bin
ding sites 
was necessary for expression, and for maximum e
xpression all 
three sites must be able to bind proteins. The
se protein 
complexes bound independently of each other, bu
t interacted 
synergistically to produce maximum expression o
f the apoAI 
gene. Papazafiri and coworkers (61) also ident
ified similar 
regions within the promoter area of the apoAI g
ene (-256 to 
+17) that were protected from the action of DN
AseI. They, 
however, also identified a 4th footprint (figur
e 3 site 4). 
Site 1 has been reported to be the binding site
 of a few 
proteins. Papazafiri, et al. (61) reported tha
t site 1 bound 
at least two distinct complexes - designated A
IDl (apoAI 
footprint D protein 1) and AID2. 
Ladias, et al. (62) reported a DNA-binding pro
tein ARP-1 
(ApoAI Related Protein -1), which is a member o
f the steroid 




"orphan" steroid hormone receptors, that also binds to site 
1. In cotransfection studies, ARP-1 acts as a negative 
factor and downregulates the apoAI expression. The ARP-1 
binding site was assayed for its ability to express a gene. 
The ARP-1 binding site was found to possess no promoter 
activity when it was assayed by itself, and therefore 
requires surrounding apoAI sequences for it to have an 
effect on expression. ARP-1 could be involved in the 
interplay of negative and positive factors that are involved 
in signal transduction as it is a member of the steroid 
receptor superfamily. It could have a possible role in 
thyroid hormone regulation of the apoAI gene because ARP-1 
binds the thyroid hormone responsive elements (62). 
Site 1 (-214 to -192) also contains a retinoic acid-
responsive element (RARE) that preferentially responds to 
retinoic acid receptor RXRa (63}. RXRa causes a seven fold 
increase in transcription by binding to site 1. This finding 
suggests that retinoids, and possibly other small 
hydrophobic molecules play a crucial role in the regulation 
of the apoAI expression and have a possible link to signal 
transduction. 
Site 1 has a sequence that is similar to the binding 
sequence required for LFAl (which is involved in the al 
anti-trypsin gene activation) and HNFl (hepatic nuclear 
binding factor 1). However, AID2 did not recognise a known 
binding site of LFAl, nor did the other site 1 binding 
protein ARP-1 (62) have an affinity for DNA containing a 
binding site of HNFl or LFAl. Whether or not the two 
proteins, AID2 and ARP-1 are the same has 
not been 
elucidated, but they both bind to the site
 1. 
Site 2 binds 5 protein complexes; three he
at stable positive 
factors and two heat labile factors, one o
f which is a 
negative factor (61). One of the 5 complex
es is competed out 
by NFY (histocompatible class 2 gene CCAAT
 binding factor) 
and NFY* (herpes simplex virus thymidine k
inase promoter 
binding factor) factors. 
Site 3 is only recognised by hepatic prote
ins, as DNAseI 
footprinting done with_non-hepatic protein
s isolated from 
rat spleen did not produce a DNAseI protec
tion site 3. In 
contrast site 1 was protected in the non-p
roducing cells 
(62). Site 3 might, therfore, be involved 
in tissue specific 
regulation of the apoAI gene. 
Very little is known about site 4 as no pr
oteins have been 
identified that bind this region. 
In conclusion, transcription seems to be ti
ghtly regulated 
by DNA-protein interactions which stimulat
e or repress the 
expression of the apoAI gene in response to













part of 2nd lntron 
Figure 3: A diagram representing the known footprints that 
have been reported. 
Site 1 is the binding site of the following proteins: AID1, 
AID2, ARP-1, RXRa. Site 2 is the binding site of 5 
complexes, and site 3 seems to recognize HepG2 nuclear 
proteins; and not much is known about site 4. CAAT and TATA 
represent the CAT and TATA boxes respectively. This 
-256.+397 region also contains the 1st and part of the 2nd 
introns. 
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1.7 COORDINATE REGULATION OF THE APOAI GENE AND THE 
OTHER 
APOLIPOPROTEIN GENES: 
The tight coordinate regulation of lipoprotein gene 
expression could be a vital feature of cholesterol 
homeostasis so that a balance of lipoproteins can be
 
maintained for efficient transport of cholesterol. I
n order 
to coordinate regulation, the genes involved must ha
ve 
common protein binding sites. 
The apoAI and apoCIII genes lie next to each other i
n 
reverse orientation, and share the 3
1 flanking regions. It 
has been shown that the expression of the 5' flankin
g 
elements of the apoAI and apoCIII genes are regulate
d by the 
shared 2.1 kilobase pairs (kb) 3
1 region (70). Four proteins 
have been shown to bind to the intergenic region, ho
wever, 
they do not bind to the 5
1 flanking regions (70). It is 
postulated that these proteins, by binding to the 3
1 region, 
inhibit the 5' and 3' regions from interacting with 
each 
other, and they are hence called silencers. Possibly
 the 3' 
region is a cis-acting element that affects the bind
ing of 
proteins to DNA in the promoter regions of the two 
apolipoproteins. 
However, methylation of the apoAI-CIII-AIV gene clu
ster does 
not occur as one entity and the genes are individua
lly 
demethylated in expressing tissues (69). 
The first 500bp of the apoAI flanking region contain
s a high 
GC content. This pattern is also present in apoE and
 apoAII 
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genes (65). This could indicate that these regions recognize 
similar proteins and are regulated in a synchronized manner. 
A number of proteins have been reported to coordinately 
regulate the apolipoprotein genes e.g. the thyroid hormone, 
the AID2 and the ARP-1 proteins (61,62). The thyroid hormone 
regulates the apoAI, apoAIV and apoB independently in a 
tissue specific manner (59). The protein AID2 binds both 
apoAI and apoB promoter regions (61) and it is possible that 
these two genes are coordinately regulated. The ARP-1 
protein binds to regions in apoB, apoCIII, insulin and 
ovalbumin genes, and appears to regulate both the apoAI and 
apoCIII genes negatively (71,62). The binding of ARP-1 to 
the promoter regions of apoB, apoCIII and apoAI could be 
related to the regulation by the thyroid hormone as both 
bind to the same region, the thyroid hormone responsive 
element. 
This data suggests that the genes encoding the 
apolipoproteins are coordinately regulated by similar 
proteins in order to maintain a balance between 
lipoproteins. 
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1.8 RESTRICTION FRAGMENT LENGTH POLYMORPHISMS OF THE APOAI 
GENE: 
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The association of HDL and apoAI levels with restriction 
fragment length polymorphisms (RFLPs) in the apoAI gene have 
been extensively studied (72,73,74,75,76). RFLPs are 
mutations in the genome that have altered restriction enzyme 
sites so that the sites are either absent or present. The 
majority of RFLPs are silent mutations in that they have no 
direct functional effect on a particular gene, but are 
linked to mutations that cause functional differences. RFLPs 
could also detect mutations that lead to altered gene 
products. Four RFLPs within the apoAI gene have been 
studied: the XmnI and the MspI sites, which are 5'of the 
apoAI gene, and the PstI and the SstI sites, which are 3 1 of 
the apoAI gene (figure 4). 
The rare P2 allele of the PstI RFLP represents the absence 
of the PstI cutting site. The P2 allele was found to be 6 
fold higher in patients with low levels of HDL compared to 
control individuals (review 76). The P1P2 patients were 
found to have a higher frequency of low apoAI and HDL-C 
levels compared to PlPl individuals (76). This suggests that 
the P2 allele predisposes individuals to the development of 
CAD by lowering the levels of serum apoAI and HDL. However, 
in another study of normal individuals, the P2 allele was 
found to be associated with higher levels of apoAI and the 
variation at the PstI site was associated with 6% of the 
variation in the apoAI plasma concentrations (75). 
The discrepancy between the vario
us studies could probably 
be due to a secondary factor that
 interacts with the 
variation associated with the P2 
allele. The secondary 
factor could be either an envirom
ental factor or a variation 
at a second gene locus. 
I ApoAI gene 







Figure 4: A diagram of the RFLPs fo
und in the apoAI gene. 
The coding region of the apoAI ge
ne is represented by the 
box. X represents the XmnI sites;
 S - the SstI sites; 
M - the MspI site; and P - the Ps
tI sites. The asterisk at 
some of the sites indicate the va
riable sites. The bottom 
panel indicate the size fragments
 obtained when the DNA in 
digested with the relevant restri
ction enzymes. 
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The XmnI polymorphism exhibited an increased frequency in 
patients with hypertriglyceridaemia (76). In a different 
study patients with hypertriglyceridaemia had a higher 
frequency of the rare allele of the SstI RFLP than normal 
patients. The higher frequency is associated with type IV 
and type V hyperlipodaemia and not with type III 
hyperlipodaemia (76). 
AG to A point mutation was found at position -76 in the 
promoter region of the apoAI gene (14) and this results in 
the destruction of the MspI recognition site. The loss of an 
MspI cutting site at position -76 (A-76) has been shown to 
be associated with higher apoAI levels in men (77) and in 
another study (44), the rare allele has been associated with 
higher HDL-C and apoAI levels in women, but not in men. The 
association was also studied in Belgian boys (77) and 
children of both sexes from Brugge. In both studies the rare 
allele was associated with higher apoAI levels. The A-76 was 
found to have a frequency of 11% in the population, but 
rises to 25% in a group of hyperalphalipoproteinemic 
individuals (apoAI > 180mg/dl) (72). The association of the 
rare allele with hyperalphalipoproteinemic patients was 
confirmed in a subsequent study (72). 
These associations lead to the suggestion that the G to A 
substitution may cause enhanced apoAI transcription and 
hence increased apoAI production, as the G to A point 
mutation is in the promoter region of the gene. However, 
Smith, et al. (78) have associated an 11% reduction of apoAI 
turnover with the A-76 polymorphism. The possibility that 
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the G to A is a marker that is associated with another 
mutation elsewhere in the gene can not be overlooked. 
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1.9 THE AIM OF THIS PROJECT: 
The aim of this project was to determine i
f the G to A point 
mutation in the promoter region of the apoA
I gene was 
functionally significant and deals with the
 possiblities 
that the G - A could cause altered transcr
iption of the 
apoAI gene. The A at -76 has been associate
d with higher 
apoAI levels in various groups (14,72,77), 
and this could be 
attributed to two factors. Firstly the apoA
I could be a 
genetic marker for higher apoAI levels and
 is closely linked 
to the causative mutation elsewhere in the
 gene, or 
secondly, the G to A mutation could result 
in an increase in 
apoAI levels and therefore have a function
al role in 
promoting the expression of the apoAI gene
. 
The G to A substitution creates a bipartite
 repeat CAGGG 
CaGGG (the lower case 'a' is the position 
of the -76 G to A 
point mutation). This repeat also lies betw
een the TATA box 
at -30 and the CAAT sequence at -105 and a
butts a DNAseI 
footprint site (-128 to -77), which was pr
esent when the 
promoter with the G at -76 was analysed (6
1). In considering 
the location of the mutation, it is highly
 concievable that 
it would alter the apoAI promoter activity.
 
Therefore, experiments analysing the DNA-
protein binding 
potential (using gel retention assays) and
 the promoter 
expression potential (using CAT assays) we
re done to prove 
that the A mutation at -76 alters DNA-prot
ein binding and 




MATERIALS AND METHODS 
A. Materials: 
Gamma 32 P ATP and 14c chloramphenicol were purchased from 
Amersham International Corporation, UK. The restriction 
enzymes, T4 ligase, T4 polymerase and T4 polynuclear kinas
e 
were purchased from Promega, Madison, WI; and the acetyl C
oA 
from Boehringer Mannheim, Manneheim, Germany. All other 
reagents were purchased from Merck, Darmstadt, Germany; BD
H 
limited, Poole, England; and Biolab, Halfway House, RSA. 
B. Methods: 
The preparations of all the solutions are in the appendix.
 
2.1. VECTORS: 
pUC19, p8CAT and RSV Bgalactosidase were used. These vecto
rs 
all carried the ampicillin resistence gene which was used 
as 
a positive selector when the bacteria were grown on 
ampicillin containing medium. The pUC19 vector is 2.6kb, h
as 
an origin of replication for replication in bacteria and a
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polylinker cloning site with various restriction enz
yme 
sites. The p8CAT vector is 4.5kb. It consists of the
 pEMBL8 
vector and the chloramphenicol acetyltransferase 
promoterless gene and a polylinker. The p8CAT contai
ns the 
origins of replications for replicating in both the 
bacterial and eukaryote cellular systems. The RSV 
Bgalactosidase vector has the Bgalactosidase gene un
der the 
control of the Rous Sarcoma Virus (RSV) promoter. 
2.2. QIAGEN MINI PREPARATION: 
This method of DNA preparation is available commerc
ially and 
was used to purify the vectors required for DNA dige
stion. 
2.3. DNA DIGESTION: 
DNA was digested in: 
1 /10 volume of restriction enzyme 
buffer (lOX); 1 / 20 volume of BSA (2mg/ml, 
if required); 
restriction enzyme (1-2 units/µg DNA), not more than
 10% of 
final volume), and the final volume made up by the a
ddition 
of water. The reaction mixture was incubated for 3 h
ours at 
37°C (except for digestion with Smar, which was dige
sted at 
25°C). The reaction was stopped by adding 5µ1 of loa
ding 
buffer and run on a 6 % polyacrylamide gel (1 29% 
bisacrylamide: acrylamide) in lXTBE buffer. The gel 
was run 
for 2 - 3 hours at constant voltage. 
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2.4. DNA MARKERS: 
Three types of DNA markers were used as standards: PvuII 
marker, MspI marker and pGEM marker. The PvuII marker was 
obtained by digesting lambda DNA (Promega) with the 
restriction enzyme PvuII; the MspI marker was obtained by 
digesting the pBR322 vector with MspI restriction enzyme and 
the pGEM marker was a commercially obtained marker 
{Promega). 
2.5. DNA ELUTION: 
The polyacrylamide gel was stained with ethidium bromide 
(EtBr) and visualized under ultraviolet light. The DNA 
markers were used to size the fragments and the fragments of 
interest were cut out of the gel and eluted in 350µ1 of 
crush-soak-solution and left over night in a shaker at 37°C. 
After a five second spin in the microfuge, the 350µ1 
solution was removed, 200µ1 fresh crush-soak-solution was 
added to the gel, gently mixed and then removed. The 500µ1 
crush-soak-solution was then ethanol precipitated, either 
overnight at -20°c or for one hour at -70°C, with two 
volumes of 96% ethanol and 10% of the original volume of 2M 
sodium acetate pH 5.4. The mixture was spun in a microfuge 
at 4°C for 15 minutes, and the pellet washed with 200µ1 70% 
ethanol and spun for 10 minutes. The pellet was vacuum dried 
in a speedy vac for 15 minutes with no heat and the DNA 
pellet was resuspended in lXTE buffer. 
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2.6. DNA BLUNT ENDING: 
5µg of digested DNA was blunt ended with 2.5 units of T4 D
NA 
polymerase in 1 ; 10 volume T4 DNA polymerase
 buffer (lOX 
Boehringer Manneheim buffer A); 
1 /10 BSA (lmg/ml) and the 
final volume was made up to 20µ1. The reaction was incubat
ed 
at 37°C for 15 minutes, after which lµl (2mM dNTPs) was 
added and incubated for a further 15 minutes at 37°C. The 
DNA was ethanol precipitated as previously described. 
2.7. VECTOR DEPHOSPHORYLATION: 
Calf intestinal phosphatase (CIP) was used to 
dephosphorylate DNA (1 - 5µg) in 
1 /10 volume of CIP buffer 
(lOX) (Boeringer Manneheim), 
1 /30 volume BSA (2mg/ml), 1 
unit of CIP enzyme at 42°C for 5
1 protruding ends, or 56°C 
for 3' and blunt ends, for 30 minutes (extact volumes woul
d 
depend on total volumes). An alternative method was also 
used to dephosphorylate at 37°C for two 30 minute periods,
 
each period having 1 unit of CIP enzyme added. The reactio
n 
was stopped by adding 
1 ; 10 volume of EGTA (50mM), and t
he 
mixture incubated at 90°C for three minutes. The reaction 
mixture was then subjected to two phenol extractions, 
followed by a chloroform:isoamyl alcohol (24:1) extraction
. 
These extractions could be substituted for a 
phenol:chloroform (1:1), and a chloroform:isoamyl alcohol 





T4 DNA ligase was used, in 1 /10 volume ligase buffer 
(Promega), to ligate the dephosphorylated vector to the 
fragment of interest. Ligation was done either at room 
temperature overnight or at 37°C. If the reaction was to be 
stored for longer than a few hours, the reaction was stopped 
by heating it at 65°C for 10 minutes. The ligation mixture 
was stored at -20°c. Ligation controls were done i.e. 
ligation of vector that was not dephosphorylated to observe 
if the phosphorylated vector ligates; and dephosphorylated 
vector was ligated to check that the dephosphorylation 
procedure had worked. 
2.9. PREPARATION OF COMPETENT CELLS: 
DKl (E.coli bacterial cells) were inoculated from glycerol 
stocks into 100ml antibiotic free L-broth in 11 conical 
flasks. The cultures were grown overnight in a shaking 
incubator at 37°C. 1.5ml of the overnight culture was 
reinoculated into a fresh antibiotic free 100ml L-broth, 
grown at 37°C for two hours, and centrifuged at 4°C in a 
Beckman TJ-6 benchtop centifuge at 2500rpm for 10 minutes. 
The resulting pellet was resuspended in 40ml of cold 60mM 
cac1 2 ,1oomM Pipes pH 7.2, and left on ice for 30 minutes. 
The suspension was centrifuged in the TJ-6 benchtop at 
2500rpm for 10 minutes at 4°C. The pellet was resuspended in 
36 
4ml of 60mM cac12 ,1omM Pipes pH 7.2, 15% glycero
l. The 
suspension was aliquoted into 200µ1 aliquots, quick frozen 
in liquid nitrogen and stored at -70°C. 
2.10.TRANSFORMATION: 
Competent DKl cells (100µ1) were thawed on ice, after which 
5µ1 of the ligation mixture was added to the cells, and left 
to incubate on ice for 30 minutes. The cells were heat 
shocked at 42°C for two minutes in 10ml tubes. Prewarmed 
antibiotic free L-broth medium (1ml) was added to the 
competent cells and incubated for 60 minutes at 37°C. The 
transformed cells were plated out on agar plates (10cm in 
diameter) with 1% ampicillin (5mg/ml) and incubated 
overnight at 37°C. Transformation controls were done i.e. 
intact circular vector was used as a control for 
transformation. The positive colonies (the colonies that 
contained vector plus an insert) were picked from the 
overnight agar plates and inoculated into 10ml L-broth with 
1% 5mg/ml ampicillin in 50ml tubes. The cultures were grown 
overnight at 37°C in a shaking incubator. 
2.11. RAPID PLASMID PREPARATION: 
The overnight 10ml cultures (from section 2.10} were used to 
extract the plasmid. Two aliquots (1ml) of the cultures were 
spun in eppendorfs at 4°C for 5 minutes. The pellet was 
resuspended in solution 1 (100µ1) and left at room 
37 
temperature for five minutes. Solution 2 (200µ1) was added 
and left on ice for five minutes. Solution 3 (150µ1) was 
added for 5 to 10 minutes on ice. The mixture was gently 
mixed to encourage a course white precipitate to form and 
the solution was centrifuged in a microfuge at room 
temperature for 5 minutes. The supernatant was removed and 
was precipitated with one volume of isopropanol at -20°c for 
30 minutes. The solution was microfuged at 4°C for 10 
minutes, the pellet washed with 70% ethanol and spun for 5 
minutes at 4°C. The pellet was dried in a speedy vac for 15 
minutes and dissolved in lXTE. The DNA concentration was 
estimated by measuring the optical density of the solution, 
and by using the conversion factor of 1 OD unit at 260nm 
being equivalent to 50µg/µg. 
2.12. PLASMID CHECK AND SELECTION: 
The plasmids were checked for either the presence or absence 
of a fragment by digesting with the appropriate restriction 
enzyme. The digests were electrophoresed either on 1% 
agarose or a 6% polyacrylamide gels. The clones that 
produced a positive result were selected and the original 
10ml culture from Rapid Plasmid Preparations was regrown 
overnight and aliquotted into glycerol stocks i.e. 0.5ml of 
bacteria culture added together with 0.5ml 100% glycerol 
into 1ml tubes. The contents were mixed and allowed to stand 
for 4 hours before storing at -70°C. 
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2.13. CLEAR LYSATE PREPARATION: 
Each positive clone (50µ1 from glyerol stocks) was 
inoculated into separate L-broth medium (11 in a 21 conical 
flask) with 1% ampicillin (5mg/ml) and incubated overnight 
at 37°C in a shaking incubator. The cells were havested by 
centrifugation in a Beckman centrifuge at aooorpm at 4°C for 
10 minutes in a JAlO rotor. The pellet was resuspended on 
ice in suspension buffer (10ml) and left on ice for 5 
minutes. Lysozyme buffer (4ml) was added and the mixture was 
left on ice for five minutes, occasionally gently swirling 
it. After which 250mM EDTA pH 8 (6ml) was added and again 
left on ice for 5 minutes. After slowly adding the lysis 
buffer (16ml) to the suspension, it was left on ice for 20 
minutes. The mixture was gently swirled every 5 minutes. 
After 20 minutes the suspension was decanted into 30ml 
plastic centrifuge tubes and centrifuged at 19000rpm in a 
Beckman JA20 rotor at 2 - 4°C for 60 minutes to separate the 
chromosomal DNA and the cell debris from the plasmid DNA. 
2.14. CESIUM CHLORIDE EXTRACTION: 
Cesium chloride (lg CsCl/ml supernatant) was added to the 
supernatant from the clear lysate preparation. The solution 
was gently shaken to dissolve the CsCl. For every 10ml of 
lysate-CsCl mixture, 0.4ml of EtBr (lOmg/ml of water) was 
added. The solution was added to the ultracentrifuge quick 
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seal tube (+/- 35ml) to the brim with no air bubbles. If the 
plasmid mixture was not enough to fill a tube to the brim, a 
mixture of lysis buffer:CsCl:EtBr in the same ratios as 
above was made to fill the tube. The tubes were 
ultracentrifuged in a Ti60 fixed angle Beckman rotor at 
45000rpm for 40 - 60 hours, at 20°C with a maximum 
temperature set at 30°C. The bands of plasmid DNA were 
visualized under U.V. light and were either marked, cut out 
and extracted by means of a tube cutter, or a syringe and 
needle was used to extract the bands under U.V. light. The 
EtBr was extracted with butanol (butanol-water mix) in Corex 
tubes {30ml). The solution was dialysed against O.lXTE for 
approximately 24 hours at 4°C, changing the O.lXTE every 8 
hours. The dialysate was precipitated with two volumes of 
96% ethanol, 3M sodium acetate pH 5.4 {10% of the original 
volume), and centrifuged for 20 minutes at 9000rpm. The 
pellet was washed with 70% ethanol, centrifuged at 9000rpm 
for 10 minutes, dried, dissolved in sterile water and stored 
at -20°c. 
2.15. SEQUENCING: 
The sequence of the G and A alleles from -256 to +100 was 
determined using the commercially available Taq Track 
sequencing method. This method uses the Taq polymerase 
enzyme {Promega) to polymerize the denatured plasmid DNA in 
the presence of ddNTPs. After the reaction was terminated 
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the products were run on an 8% polyacrylamide 7M urea 
sequencing gel, dried and autoradiographed. 
2.16. TRANSFECTIONS: 
HepG2 cells were seeded (ensuring good cell separation) 
between 0.5 - 1.0 * 10-6 cells per dish 24 hours prior to 
transfection. six hours prior to transfection the medium 
(9ml) (minimal essential medium with 10% fetal calf serum) 
was changed. The transfection solution B which contains the 
DNA, was added dropwise to transfection solution A, which 
was agitiated by bubbling air through the solution. The 
solution was left for 30 minutes at room temperature for a 
fine precipitate to form. The precipitate was well mixed and 
1ml of the precipitate was added dropwise to a dish of cells 
covered with 9ml of medium. The cells were placed in the co2 
incubator at 37°C. The cells had fresh medium (10ml) 
replaced after 18 hours and 42 hours. 48 hours after 
transfection the dishes were washed three times with PBS 
(5ml) and incubated in TNE (1ml) for 5 minutes at room 
temperature. The cells were scraped off the dish, pipetted 
into eppendorf tubes and pelleted in a microfuge at 4°C for 
3 - 5 minutes. The pellet was resuspended in 0.25M Tris.HCL 
pH 7.8 (150µ1) and the suspension was freeze/thawed four 
times, vortexed briefly between each one. The cell debris 
was spun for 15 minutes in the microfuge at 4°C and the 
supernatant collected and stored at -20°c. The protein 
concentration was determined by the Lowry method (79). 
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2.17. ASSAYING FOR BGALACTOSIDASE ACTIVITY: 
Protein extract was added to Bgal buffer to make a final 
volume of 1ml. Bgal substrate (200µ1) was added to the tube, 
and the reaction was carried out at 37°C until an obvious 
yellow shade was observed. The reaction was stopped by 
adding lM Na 2co3 (500µ1). The reaction was carried out for 
15 to 60 minutes. Different amounts of protein extract were 
analysed until the OD reading, at 420nm, ranged between 0.2 
to 0.7. 
2.18. CHLORAMPHENICOL ACETYLTRANSFERASE (CAT) ASSAY: 
This assay was done according to Gorman, et al. (80). 
Protein extract was incubated with 2M Tris.HCL pH 7.8 
(22.5µ1), 14c chloramphenicol (5µ1), acetyl coenzyme A 
(20µ1) and the final volume of 180µ1 made up with water. The 
reaction was carried out for 60 minutes at 37°C. The 
14c 
chloramphenicol and its acetylated products were extracted 
with ethyl acetate (1ml), vortexed, spun in a microfuge for 
30 - 60 seconds, and the organic phase subsequently removed. 
The organic phase was either dried overnight in a fume hood 
or dried in a speedy vac (no heat and for two to three 
hours). The 14c products were resuspended in ethyl acetate 
(15µ1) and loaded onto pre-coated thin layer chromatography 
(TLC) aluminium silica gel 60 sheets. This was run in a pre-
equilibrated tank of solvent of chloroform:methanol 
(95:5ml). The chromatogram was run for one hour 15 minutes, 
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dried and autoradiographed at -70°C overnight. The 
autoradiograph was aligned to the chromatogram in order to 
mark the position of the 
14c chloramphenicol and the 14c 
chloramphenicol products. The marked areas were cut out and 
the radioactivity was counted for 10 minutes in the presence 
of scintillation fluid. The CAT activity was expressed as a 
percentage of the acetylated products of the total 
14c 
chloramphenicol added. Each sample was done in duplicate. 
Bgal was used to control for the uptake of DNA. The final 
CAT activity was determined by taking the Bgal activity in 
OD/hr/(µg protein extracted used in the CAT assay), and 
divided it into the CAT activity in% conversion/hr/(µg of 
protein used in the CAT assay). The final CAT activity, 
therefore, is represented as %conversion/OD. 
2.19. HEPG2 MAINTENANCE: 
The HepG2 cells were grown and maintained in minimal 
essential medium with 10% fetal calf serum in a co2 
incubator at 37°C, with the medium changed every second day. 
When 70% confluency was reached, the cells were split 1:5. 
This was done by washing the cells in PBS (5ml) and adding 
5X trypsin (5ml) for one minute. After the trypsin was 
removed, the cells were dislodged from the dish and split 
into fresh dishes. 
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2.20. RADIOACTIVE LABELING: 
A. The kinase labelled fragment method: 
This was done with DNA obtained from a plasmid digestion. 
The -133.+1 fragment was obtained by digesting the construct 
-256.+397.pUC19 with Sau3A and HindIII (figure 5A step 1). 
The isolated 532bp fragment was CIPPED (refer to section 
2.7). The CIPPED 532bp -133.+397 fragment was 5' labelled 
with 32 P gamma labelled ATP (140µCi), T4 polynuclear kinase 
(10 units), 1 ; 10 of the volume of fresh kinase buffer with 
the final volume of 10µ1. The reaction was incubated for 30 
minutes at 37°C and the fragment was purified on a G50 
sephadex column and then ethanol precipitated (figure 5A 
step 2). The 532bp labelled fragment was then digested with 
DdeI (figure 5A step 3} and identified by exposing the gel 
to autoradiograph film (figure 6). Two labelled products 
were observed, one of 400bp (DdeI (+1) to HindIII (+397)) 
and the other product of 133bp (Sau3A (-133) to DdeI (+1}}. 
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Figure 5: The steps taken to obtain radioactively labelled 
fragments for gel retention assays 
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A. A schematic diagram indicating the steps taken to obtain 
the kinased -133.+1 fragment. Step 1 represents the 
digestion of -256.+397.pUC19 with Sau3A and HindIII. Step 2 
represents the 32 p kinase labelling of the 532bp fragment 
and step 3 represents the digestion of the labelled 532bp 
fragment with DdeI to produce the 5' -133.+1 fragment used 
for gel retention assays. 
B. The diagram indicating the procedure taken taken to 




Figure 6: An autoradiograph of the 532bp (-133.+397) 
fragment digested with DdeI. 
Lane 1 represents the DdeI digestion of the G fragment and 
lane 2 represents the A fragment digested with DdeI. The 
397bp and 133bp bands represent the +l.+397 and -133.+1 
fragments. 
B. The PCR kinase method: 
The oligomer -140(5 1 -CAGAGCTGATCCTTGAACTC-3')-120, 
corresponding to the -133 Sau3A site of the promoter region 
of the apoAI gene (Sau3A oligo - 67ng), was also 5' end 
labelled by using the T4 polynuclear kinase (10 units), 
32 P 
gamma labelled ATP (140µCi) and 1 /10 of the volume fresh 
kinase buffer with a final volume of 10µ1. The reaction was 
performed at 37°C for ten minutes and inactivated at 90°C 
for two minutes. The labelled oligomer was used as one of 
the primers for the PCR reaction (figure 5B). 
2.21. POLYMERASE CHAIN REACTION: 
The preparation of the PCR reaction was executed in a 
laminar flow hood with pipettemans which had been 
decontaminated in lM HCL overnight. The following quantities 
were used per tube: 5µ1 lOX Promega buffer, 5µ1 (2mg/ml) 
Promega BSA, 4µ1 2mM dNTPs, lµl DdeI primer (67ng) 
+1(5'-CTCGCAGTCTCTAAGCAGCC-3 1 )+20 corresponding to the +1 
position (in reverse orientation), lµl (5 units/µl) Tag 
polymerase (Promega), 10µ1 kinase labelled Sau3A oligo 
(67ng), lµl 0.25µg DNA and 23µ1 water. A control sample with 
no DNA and non-radioactivly labelled oligos was made. The 
incubation mixture was overlayed with oil (Sigma mineral 
light white oil). 
The following program was employed: 93°C for 5 minutes, 62°C 
for 2 1 ; 2 minutes, 72°C for 3 minutes, and then 30 cycles of 
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(93°C for 1 ; 2 minute, 62°C for 1 minute, 72°C for two 
minutes). The PCR products were separated on a 6% 
polyacrylamide gel in lXTBE buffer. The bands were 
identified, cut out, the DNA eluted overnight and 
precipitated with ethanol (two volumes, overnight at -20°C). 
The pellet was dissolved in a volume that gave 1000 
counts/µl. 
The PCR products were tested for possible contamination by 
digesting the fragment with MspI which will differentiate 
the G allele from the A allele. An aliquot of labelled 
-140.+10 fragment was checked to determine if the G/A at 
-76 was the appropriate base pair (figure 7). The presence 
or absence of the MspI restriction enzyme site was used to 
determine which base pair was at the -76 position. The 
results of the MspI digestion clearly indicates that the G 
fragment was digested to a smaller fragment and the A 
fragment was not digested with MspI. As only one end, the 
Sau3A end, was radioactively labelled, there was one band 




1 2 3 4 
Figure 7: The autoradiograph of -140.+10 PCR product 
digested with MspI. 
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Lanes 1 and 4 represent the undigested G-140.+10 and 
A-140.+10 fragments respectively, and lanes 2 and 3, the 
G.-140.+10 and A.-140.+10 fragments digested with MspI. The 
top bands represent the 150bp (-140 to +10) and the bottom 
band represents the 64bp (-140 to -76), which indicates the 
presence of the MspI digestion site. {The other band (-76 to 
+10) was not radioactively labelled and hence was not 
revealed with autoradiograph film. 
2.22. NUCLEAR EXTRACT PREPARATION: 
Two methods of extracting nuclear proteins were used. 
A. The method of extracting nuclear proteins according to 
Dignam, et al. (81) 
After the medium was removed from the HepG2 cells, PBS was 
added and the cells were scraped off with a teflon 
policeman. The cells were harvested in a Beckman TJ-6 
centrifuge for 3 minutes at 4°C at 2000rpm. The pellet of 
cells was resuspended and washed in 5 volumes of ice cold 
PBS, and the cells were repelleted at 2000rpm for 5 minutes 
at 4°C. Five volumes of PCV of Dignam buffer A was used to 
resuspend the cells and they were then left to swell on ice 
for 10 minutes. The cells were respun at 2000rpm for 5 
minutes at 4°C, and then resuspended in 2 volumes of the 
original PCV of Dignam buffer A. The cells were lysed with 
10-15 strokes of a Dounce homogenizer (glass tight fitting). 
The nuclei were pelleted at 2000rpm for 10 minutes at 4°C in 
corex tubes (15ml). The supernatant was carefully discarded 
and the nuclei were pelleted again at 13000rpm at 4°C in a 
Beckman JA-20 rotor for 20 minutes. The nuclei were 
resuspended in Dignam buffer Cina concentration of 3ml per 
10-9 cells. The nuclei were homogenized in the Dounce 
homogenizer with 10-15 strokes, and transferred to 50ml 
tubes. The homogenenizer was washed off with 200µ1 of Dignam 
buffer C. The solution was gently stirred for 30 minutes on 
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ice and the solution was spun in Corex tubes (30ml) at 
13000rpm for 30 minutes at 4°C in Beckman JA-20 rotor. The 
supernatant was dialysed at 4°C against 50 volumes of Dignam 
buffer D for 5 hours. The dialysate was centrifuged at 
3000rpm for 20 minutes at 4°C in Beckman JA-20 rotor. The 
supernatant was divided into aliquotes (20µ1) and quick 
frozen in liquid nitrogen and stored at -70°C. 
B. The method of extracting nuclear proteins according to 
Lee, et al. (82). 
The monolayer HepG2 culture was harvested with a Teflon 
policeman and the cells washed in 30 volumes of cold PBS. 
The cells were centrifuged at 2000rpm for 5 minutes at 4°C 
in a Beckman TJ-6 benchtop. The packed cells were 
resuspended in one volume buffer A and allowed to swell on 
ice for 15 minutes. The cells were lysed by five cycles of 
slow aspiration and rapid ejection of the cell suspension 
using a 10ml syringe with a 22 gauge needle, that was 
prewashed with buffer A in order to prevent excess air from 
accumulating. The homogenate was spun in a microfuge at 4°C 
for 20 seconds and the pellet was resuspended in buffer C 
( 2 /3 packed cell volume), and stirred on ice for 30 minutes. 
The suspension was spun in a microfuge for 5 minutes at 4°C 
and the supernatant was dialysed for two hours against 50 
volumes buffer D. The supernatant was aliquoted, frozen in 
liquid nitrogen and stored at -70°C. 
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2.23. GEL RETENTION ASSAYS: 
Five times incubation buffer (5µ1), poly didC (1 - 8µg) and 
nuclear proteins were incubated at room temperature for 10 
minutes, to which lµl labelled probe was added (details 
indicated in legends of the figures). This was incubated for 
a further 30 minutes on ice. For the competition studies the 
probe was incubated for 10 minutes on ice, then the 
competitor was added for a further 20 minutes on ice. 5µ1 
loading buffer was added and the reaction mixture was loaded 
onto a pre-electrophoresed 5% polyacrylamide gel run in 
0.5XTBE buffer. The gel was run at 4°C under constant 
voltage of 150V for approximately five hours. The gel was 
dried on a vacuum drier for 1 1 /2 hours with one hour heated 
at 60°C and autoradiographed overnight at -70°C. 
2.24. STATISTICAL ANALYSIS: 
A pair wise, and non-pair wise student t tests were used to 






All the constructs were made in duplicate i.e. one of the 
duplicates contains a guanosine at the -76 position and the 
other contains an adenosine at position -76. 
3.1. Cloning of the -256.+397.p8CAT construct: 
The -256.+397 (650bp) fragment of the apoAr promoter region 
was isolated from an apoAr.pUC13 construct that contained a 
2.85kb Hindrrr.Hindrrr fragment that encompassed the apoAr 
promoter region (figure 8A step 1). The fragment was 
digested with Smar and Hindrrr to release a 650bp fragment 
(-256 to +397), which was identified, isolated and ligated 
into the Smar and Hindrrr sites of the p8CAT polycloning 
site (figure 8A step 2). The constructs were checked by 
releasing the fragment with the restriction enzymes Smar and 
Hindrrr, and by sequencing the construct with the Taq Track 
method (refer to section 2.15). The constructs were 
determined to be 650bp in length (figure 8B) and the two 
constructs possessed the appropriate G or A at the -76 















Figure SA: A schematic diagram of the steps taken to 
construct the -256.+397.pSCAT construct. 
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1 represents the digestion of the apoAI.pUC13 construct with 
Smar and HindIII, to release a 650bp (-256.+397) fragment. 
2 represents the ligation of the 650bp fragment into p8CAT 
to produce -256.+397.pBCAT. CAT, above the box, represents 




Figure SB: A photograph of a 1% agarose gel showing the 
release of the 650bp fragment from the -256.+397.pSCAT 
constructs. 
Lanes 1 and 2 represent the G.-256.+397.pSCAT and 
A.-256.+397.pSCAT digested with Smar (-256) and Hindrrr 
(+397) to release a 650bp fragment. 
3.2 Cloning of the -256.+397.swop.pSCAT construct: 
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The 300bp in the 3 1 region of the G.-256.+397.pSCAT 
construct was swopped with the 300bp in the 3
1 region of the 
A.-256.+397.pSCAT construct. This was done by releasing the 
+100.+397 300bp fragment (figure 9A step 1), swopping the 
two 300bp fragments (figure 9A step 2) and ligating them 
into the crPPED p8CAT constructs (figure 9A step 3). The 
constructs were checked for the correct size by digesting 
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Figure 9A: A diagram of the steps taken to construct the 
-256.+397.swop.pSCAT constructs. 
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1 and 2 represent the digestion of G.-256.+397.p8CAT and 
A.-256.+397.p8CAT respectively with KpnI (+100) and HindIII 
(+397). 3 and 4 represent the swopping of the two 300bp 
fragments and ligating them into the acceptor constructs to 
produce the swop constructs. 
Figure 9B: A photograph of a 1% agarose gel showing the 
release of a 650bp fragment from the swop constructs. 
Lane 1 represents the PvuII DNA marker. Lanes 2 and 3 
represent G.-256.+397.swop.p8CAT and A.-256.+397.swop.p8CAT 
respectively digested with Smar (-256) and HindIII (+397) to 
release the 650bp fragments. 
3.3 Cloning of the -133.+397.p8CAT construct: 
An indirect method of cloning the -133.+397 (Sau3A-HindIII) 
fragment was used, as the p8CAT vector has many Sau3A sites 
and therefore could not be used for Sau3A digestion. The 
-256.+397 650bp fragment was digested from p8CAT (figure 9A 
step 1) and ligated into CIPPED pUC19 (figure lOA step 2). 
The construct was purified, by using the Qiagen method 
(refer to section 2.2), and checked by releasing the 
SmaI.HindIII 650bp fragment. The -256.+397.pUC19 construct 
was digested with Sau3A and HindIII (figure lOA step 3) and 
the 532bp -133.+397 fragment was isolated and ligated into 
the BamHI and HindIII dephosphorylated sites of the p8CAT 





















Figure lOA: A schematic diagram of the procedure followed to 
construct the -133.+397.pSCAT construct. 
1 represents the digestion of -256.+397.pBCAT with Smar 
(-256) and HindIII (+397), releasing the 650bp fragment, 
which was ligated into pUC19, represented by 2. 3 represents 
the digestion of -256.+397.pUC19 with Sau3A (-133) and 
HindIII (+397), and 4 represents the insertion of the 532bp 
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Figure lOB: A photograph of a 1% agarose gel showing the 
release of a 532bp fragment. 
Lane 1 represents the PvuII DNA marker. Lanes 2 and 3 
represent G.-133.+397.pSCAT and A.-133.+397.pSCAT digested 
with Barn.HI and HindIII to release 532bp fragments. 
An explanation on how the Sau3A site "transformed" into the 
Barn.HI site: 
Sau3A restriction enzyme is a 4bp cutter i.e. it recognizes 
a consensus site of 4bp GATC. Barn.HI restriction enzyme is a 
6bp cutter GGATCC, with the middle 4bp being the consensus 
site for Sau3A. Sau3A and Barn.HI sites, when cut with the 
restriction enzymes, create compatible sticky ends (figure 
11). In the apoAI promoter there is a Sau3A site at -133, 
the base pair 3 1 of the site is a C, which is correct for a 
59 
BamHI site, but the 5' base pair is a T which is incorrect 
for a BamHI site (figure 11). However, when the BamHI site 
in the p8CAT's polylinker and the Sau3A site in the fragment 
are ligated, a "new" BamHI site is formed (figure 11). This 
enables the 532bp fragment to be released from the p8CAT by 
digesting it with BamHI and HindIII. This was done to check 
for the presence of the fragment (figure lOB). 
f • 
GGATCC CTGATCC 
CCTAG~ \ / GACTAG!3 




p8CAT CCTAG G ApoAI promoter 
Figure 11: A diagram illustrating how the BamHI restriction 
cleavage site was formed from the sau3A and BamHI sites. 
1 represents the digestion of p8CAT vector with BamHI, 
producing a BamHI sticky end; while 2 represents the 
digestion of the apoAI promoter with Sau3A, producing a 
BamHI-compatible Sau3A sticky end. 3 represents the ligation 
of the Sau3A and BamHI sites resulting in a BamHI site. 
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3.4 Cloning of the -256.+68.p8CAT construct: 
The -256.+397.p8CAT was digested with StuI and HindIII 
(figure 12A step 1), and a 330bp fragment was released. The 
resultant linear p8CAT vector containing the SmaI.StuI 
fragment was blunt ended with T4 DNA polymerase (refer to 
section 2.6) and religated (figure 12A step 2) to produce 
the -256.+68.p8CAT construct. The construct was positively 
identified by sequencing it using the Tag Track method 
(refer to section 2.15). Both the A and the G constructs 
were found to be the correct length (330bp) and the 











Figure 12: A diagram showing the steps taken to construct 
the -256.+68.pBCAT construct. 
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The digestion of -256.+397.p8CAT with stuI (+68) and HindIII 
(+397) is represented by 1. 2 represents the blunt ending 
and ligating of the -256.+68.p8CAT construct. 
CHAPTER 4 
RESULTS 
4.1. EXPRESSION OF THE APOAI PROMOTER 
CAT ASSAYS 
The promoter strength of a fragment can be assayed by 
placing it in front of a promoterless reporter gene, 
transfecting it into a cultured cell line and assaying for 
the protein product of the gene. The gene of the bacterial 
enzyme, chloramphenicol acetyltransferase (CAT) was used as 
the reporter gene. The fragment with putative promoter 
activity drives the production of the CAT mRNA and CAT 
protein. The amount of CAT protein is determined by assaying 
the activity of the enzyme. The CAT protein acetylates 
14c 
chloramphenicol in the presence of acetyl coenzyme A. The 
acetylated products and the substrate can be separated on 
thin layer chromatography (TLC) plates. A typical 
autoradiograph of the TLC plate is represented in figure 13. 
The Bgal construct (refer to section 2.1), was cotransfected 
with each of the p8CAT constructs This was done in order to 
control for DNA uptake by the HepG2 cells in the different 
dishes, because with the method used to transfect the HepG2 
cells i.e. the CaPo4 method, DNA is taken up in the same 
~atio as prepared in the test-tube. In this study 
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G.-256.+397.p8CAT refers to the G at -76 within the region 
-256 to +397 inserted into the p8CAT vector and the A 
constructs are the vectors with the A at -76. After the 
final CAT activities were determined (as described in 
section 2.18), the final CAT activity of the G construct was 
allocated a relative CAT activity of 1 and the A construct's 
final CAT activity was expressed relative to the CAT 










Figure 13: An autoradiograph of a TLC plate of a typical 
result obtained from the CAT assays. 
Spot 1 represents the origin where the mixture was spotted 
onto the TLC plate. Spot 2 represents the unacetylated 
substrate, and spots 3 and 4 represent the mono-acetylated 
products. The difference between spots 3 and 4, is that the 
14c chloramphenicol has been mono-acetylated at different 
' 
positions. Lanes grouped as 1 and 2, represent the 
G.-256.+397.pBCAT and A.-256.+397.pBCAT respectively. 
4.1.1 -256.+397.pBCAT construct: 
The 650bp fragment has a number of potentially important 
DNA-protein binding regions which could influence the 
promoter activity, as the fragment has been identified to 
contain DNAseI footprints (60,61,62), the TATA box and the 
CAAT box, the first intron and part of the second intron 
(figure 14), which are all possible promoter regulatory 
elements. The region -256 to -41 was previously reported to 
be sufficient and necessary for transcription in HepG2 cells 
(64) and so a 650bp fragment containing this section was 
transfected into the HepG2 cell line. 
This was achieved by inserting the Smar (-256) to HindIII 
(+397) 650bp fragment of the apoAI promoter region 5' of the 
CAT gene to determine its promoter activity (refer to 
section 3.1). CAT activities of the G.-256.+397.pBCAT and 
A.-256.+397.pBCAT constructs were calculated as previously 
described and are compared in Table 1. 
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Figure 14: A diagram of the 650bp fragme
nt indicating the 
positions of the DNA-protein binding reg
ions reported by 
Papazafiri, et al. (61) and the restrict
ion enzyme sites 
used in this project. 
The DNA-protein regions are represented
 by the boxes 
labelled 1 - 4. CAAT and TATA represen
t the CAT and TATA 
boxes. The G to A point mutation at -7
6, restriction enzyme 
sites, DNA-protein binding regions and
 the 1st and part of 
the 2nd intrans are also represented in
 this diagram. 
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Table 1: CAT activities of the -256.+397.pBCAT constructs. 
Each experiment represents three dishes which were assayed 
in duplicate. Each dish was normalized for DNA uptake with 


























p value= 0.002 
When the activities of G.-256.+397.pSCAT and the 
A.-256.+397.pSCAT constructs were compared, the 
A.-256.+397.pSCAT construct had higher CAT activity than the 
G.-256.+397.pSCAT construct (1.91 vs 1 respectively) (Table 
1). The result was statistically significant with a p value 
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(probability value) of 0.002. This result indicates that 
when the -256.+397.p8CAT construct was assessed, the 
presence of the A at -76 influences the promoter activity 
and results in an increase in the activity of the apoAI 
promoter in HepG2 cells. 
4.1.2. -256.+397.swop.p8CAT construct: 
The sequence difference of the +100 to +397bp fragment 
between the G and A alleles was not known. So the influenc
e 
of any variations in the 300bp (+100 to +397) fragment was
 
assessed for its effect on the expression of the apoAI 
promoter. 
This was done by swapping the +100 to +397 fragments of th
e 
G and A constructs (details in section 3.2). The construct
s 
were isolated, purified and cotransfected with Bgal into 
HepG2 cells, as previously described. 
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Table 2: CAT activities of the -256.+397.swop.pSCAT 
constructs. 
Each experiment is represented by three dishes which were 
































p value< 0.0001 
Results obtained from the swap experiments (Table 2} 
indicate that the A.-256.+397.swop.pSCAT, containing the 
+100 to +397 region of the G construct, had a higher CAT 
activity than the G.-256.+397.pSCAT, containing the +100 to 
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+397 region of the A construct, (2.09 vs 1 respectively) 
with a p < 0.0001. 
Table 3: comparative analysis of the relative CAT activity 
results obtained from A.-256.+397.pSCAT (Table 1) and from 
A.-256.+397.swop.pSCAT (Table 2). 
A.-256.+387.p8CAT 
















p value= 0.61 
The CAT activities of the original A.-256.+397.p8CAT vector 
and the A.-256.+397.swop.p8CAT were compared in Table 3. 
There was no significant difference between these two 
constructs. The 300bp fragment (+100 to +397) does not 
appear to affect the expression of the CAT gene when the 
300bp was swapped between the G and A constructs. Any 
sequence differences between the two constructs has, 
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therefore, no effect on the promoter activity of the 650bp 
(-256.+397} constructs. 
4.1.3. -133.+397.pBCAT construct: 
The region -256 (SmaI) to -133 (Sau3A} contains two major 
DNAseI footprint sites (figure 14). The expression of the 
fragment (-133 to +397) was previously reported to have a 
120 fold less CAT activity than the fragment, -256 to +397 
(60). This result clearly indicates that the region from 
-256 to -133 has strong promoter activity. If this region is 
absent, does the A at -76 cause an effect on the activity of 
the promoter strength? This question was answered by 
constructing a -133.+397.pBCAT construct (detailed in 
section 3.3). 
The resultant CAT activities from the constructs 
G.-133.+397.pBCAT and A.-133.+397.pBCAT, were very low; too 
low for a difference to be assessed between the G and the A 
constructs. Hardly any conversion of 
14c chloramphenicol was 
observed, even when the incubation time was extended to 3 
hours and more acetyl coenzymeA was added. The activity was 
more than 14 fold less than that of the activity of the 
G.-256.+397.pBCAT construct (Table 4). The control (p8CAT 
with no insert) was designated a relative CAT activity of 
one, and the other constructs used in the experiment were 
calculated relative to the control. 
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Table 4: CAT activities of the -133.+397.pSCAT constructs. 
Each dish was normalized with Bgal and each experiment 
represents three dishes assayed in duplicate. The G 
represents the G allele of the -133.+397.p8CAT, and the A, 
the A allele of the -133.+397.p8CAT. The control was the 
p8CAT vector with no inserted promoter fragment. 
-133.+397.pSCAT 
Experiment Control G.-256.+397.p8CAT 




















p value= 0.0866 
The mean CAT activity of the G.-133.+397.p8CAT and 
A.-133.+397.p8CAT constructs was different, however, this 
difference was not significant. This result indicates that 
the 5' region -256 to -133 region is necessary for maximum 
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expression of the promoter and that the region -133 to +397 
has minimal promoter activity, which agrees with results 
previously reported (60). 
4.1.4. -256.+68.p8CAT construct: 
A smaller fragment of 320bp from Smar (-256) to stuI (+68) 
was constructed as described in section 3.4, and was assayed 
to determine if the sequences 3' of this fragment influence 
the activity of the apoAI promoter. This construct was also 
made as it had been previously reported that when the 
-256.+68 promoter region was investigated (78), the G allele 
had greater activity than the A allele in vivo. 
Tables: The CAT activities of the -256.+68.pSCAT 
constructs. 
Each experiment represents triplicate dishes, each dish was 
assayed in duplicate and normalized with their Bgal 
activities. G represents the construct G.-256.+68.p8CAT and 
the A, the A.-256.+68.p8CAT. G.-256.+397.p8CAT was used as a 
control and was assigned a value of 1 so that this result 
can be compared to previous results. 
-256.+68.pSCAT 
Experiment G.-256.+397.p8CAT 
1 1 3.25 4.21 
2 1 3.04 3.01 
3 1 2.52 2.89 
4 1 4.57 4.48 
5 1 4.94 4.55 
Mean 
1 3.66 3.83 
Std Deviation 
+/-1. 04 +/-0.81 
p value= 0.5202 
These results (Table 5) indicate that the G and A constructs 
have no significant difference in CAT expression when the 
-256.+68 fragment of the apoAI promoter is assessed. This 
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indicates that the difference between the G and A promoters 
results from a possible interaction between regions 
surrounding the -76 mutation and regions 3 1 of the position 
+68. 
4.2. DNA-PROTEIN INTERACTIONS 
GEL RETENTION ASSAYS: 
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Cellular processes e.g. replication, recombination, viral 
integration and transcription are regulated by DNA binding 
proteins. These proteins are called trans-acting factors, 
which are found in the nucleus. They regulate transcription 
via specific interactions with DNA sequences, which are 
primarily found in the promoter region of the gene. 
The presence of DNA-protein complexes are assayed by the 
ability of nuclear proteins to retard the mobility of 
radioactively labelled DNA fragments when run on a non-
denaturing polyacrylamide gel. This assay is refered to as a 
gel retention assay. The complexes are assessed by the 
presence of bands on autoradiographs. Hence, a difference in 
DNA-protein binding between two different fragments of DNA 
can be detected by a shift in the position of the bands on 
an autoradiograph. These bands are indicative of DNA-protein 
complexes, and the different bands on the gel are due to the 
formation of different DNA-protein complexes. 
-128 -77 -22 +17 
I 3 I I 4 I 
Sau3A Ddel 
I D 0 0 I 
-133 CAAT -76 TATA 
+1 
G-A 
Figure 15: A diagram of the 150bp fragment illustratin
g the 
DNA-protein binding regions of the fragment. 
TATA and CAAT represent the TATA and CAT boxes resp
ectively. 
Footprint sites 3 and 4 (61) are indicated, as well 
as the 
restriction enzyme digestion sites, Sau3A and DdeI, 
and the 
position of the G to A point mutation are indicated
. 
4.2.1 Gel Retention Assays (Kinase Method): 
The Sau3A (-133) to DdeI (+l) fragment was used in 
gel 
retention assays because it contains known protein 
binding 
sites and it contains the -76 position (figure 15). 
The 
-133.+l fragment was kinased as explained in section
 2.20. 
Gel retention was done in order to determine how ma
ny 
complexes were formed when crude nuclear proteins an
d the 
-133.+l fragments were incubated together. A differe
nce in 
DNA binding patterns between the G and A fragments w
as also 
investigated, which would be detected by a differenc
e in the 
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pattern of complexes formed (figure 16). (The G and A 
fragments are the fragments with G or A at .position -76 
respectively). Nuclear proteins were extracted by the Dignam 
method from HepG2 cells (refer to section 2.22a). The amount 
of nuclear proteins used was Sµg per lane as this was 
determined to be the optimum nuclear protein concentration 
for maximum DNA-protein binding efficiency (results not 
shown). 










LEGEND ON FOLLOWING PAGE 
Figure 16: An autoradiograph of a gel retention assay 
indicating the bands which represent the DNA-protein 
complexes. 
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Lanes 1 and 3 represent the controls which were G and A 
labelled DNA fragments respectively, incubated in the 
absence of nuclear proteins i.e. the free probe. Lanes 2 and 
4 represent the G and A fragments incubated with nuclear 
proteins. The major complexes that formed between the DNA 
and the nuclear proteins are represented as 1, 2, 3, 4 and 5 
on the autoradiograph. 
The controls were used as an indication of any contaminating 
DNA, and were also used as a reference to determine which 
band represented the free DNA fragment so that DNA-protein 
complexes could be identified in the lanes which had DNA 
that had been incubated with nuclear protein. Five main DNA-
protein complexes were observed for both the G and the A 
fragments (figure 16}. There was, however, a difference in 
the pattern of DNA-protein complexes formed between the G 
and A fragments. This was determined by taking the Rf values 
(i.e. distance travelled by complex divided by the distance 
travelled by the free labelled fragment). The Rf value for 
the G fragment complex 4A (band 4A} was 0.348, and the Rf 
value for the A fragment complex 4B was 0.367. The G 
fragment also formed band 4B (with a Rf value of 0.369), but 
it was of lower intensity than the band 4B of the A 
fragment. These results suggest that there were different 
DNA-protein interactions between the -133.+1 G and A 
fragments as the pattern of complexes formed in gel 
retention assay was different. 
DNA-protein binding in vitro (as in the above experiment) 
could be non-specific and in order to eliminate non-specific 
binding, a fragment of DNA that binds non-specifically to 
proteins was added to the reaction. Poly didC was used to 
perform this function of removing non-specific protein 
binding (figure 17). The intensity of the DNA-protein 
complexes decreased with the increasing amounts of poly didC 
as seen in lanes 2 to 5 for the G fragment and in lanes 7 to 
10 for the A fragment. The optimum poly didC was determined 
to be 4 µg per lane as lanes 3 and 8 represented clear DNA-
protein complexes, compared to the back-ground, as can be 
seen in figure 17 (unfortunately the photograph of the 
autoradiograph was not as clear as the autoradiograph). 
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Figure 17: An autoradiograph of a gel retention assay 
preformed with increasing amounts of poly didC. 
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The first five lanes represent the G fragment and the A 
fragment is represented in lanes 6 to 10. Lanes 1 and 6 were 
the controls i.e. no nuclear protein. Lanes 2 to 5 and 7 to 
10 had nuclear proteins and increasing amounts of poly didC. 
The concentrations of the poly didC are indicated below the 
photograph. 
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4.2.2 GEL RETENTION ASSAYS (PCR METHOD): 
The radioactive labelling efficiency of the kinase method 
was found to be low and involved a lot of purification steps 
whic~ resulted in loss of DNA, e.g. in the kinase method th 
effi~iency of the G was 55.21 compared to that of 851.06 
coun:s per ng of the PCR method (Table 6). To overcome these 
diff·culties the polymerase chain reaction (PCR) technique 
was •lmployed. The oligomers labelled with hiJher efficiency 
than the DNA fragment and there were fewer pirification 
step: involved with the PCR method than with the kinase 
meth<·d (figure 5B - section 2.20). 
Tabll 6: A comparison between the kinase and PCR methods of 
obta:ning radioactive fragments for gel reter1tion assays. 
(ref1r to section 2.20 for the details) The J and A 
repr, sent the G and A fragments respectively 
Efficiency 














The PCR reaction was done using the -256.+397.p8CAT 
construct, a radioactively labelled Sau3A oligomer a
nd an 
unlabelled Ode! oligomer (details in section 2.21). 
A 150bp 
fragment was amplified, and identified in both lanes
 1 and 2 
(figure 18). This fragment was 150bp in length from 
positions -140 to +10 of the apoAI gene. There was n
o 
contamination in the PCR reaction as the blank (H20)
 control 
had no contaminating DNA. 
150bp 




Figure 18: A photograph of a 1% agarose gel showing t
he 
lSObp PCR products. 
Lanes 1 and 2 represent the PCR products of the G an
d A 





The PCR labelled -140.+10 fragment was used for gel 
retention assays. The method of extracting the nuclear 
proteins was changed from the Dignam method (refer to 
section 2.22a} to the Lee method (refer to section 2.22b}, 
as the Dignam method required more HepG2 cells and also 
involved a longer protocol than the Lee method. To determine 
the optimum amounts of poly didC in the incubation mixture, 
increasing amounts of poly didC were used to compete out the 
non-specific DNA-protein interactions (figure 19). The 
nuclear protein was kept constant at 5µg/lane which was 
previously determined to be the optimum concentration 
(results not shown). 
The autoradiograph in figure 19 shows 9 DNA-protein 
complexes that had formed between the -140.+10 fragments and 
the nuclear proteins extracted according to the Lee method. 
In all of the lanes bands 3 and 5 were the darkest which 
implies that the DNA fragment had the greatest affinity for 
the nuclear proteins which formed the DNA-complexes 
represented as bands 3 and 5. The G fragment formed complex 
3, but not complex 4 (represented as band 3 and 4 
respectively), whilst the A fragment formed complex 4·but 
not complex 3. This result indicates that the G and the 
A -140.+10 fragments have different DNA-protein interactions 
in vitro. This confirms the result obtained with the -133.+1 
kinased fragment (figure 16). The increasing amounts of poly 
didC used in lanes 2 to 9 competed out the bands, and 4µg/µl 
poly didC was the optimum poly didC concentration as lanes 4 
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and 5 (representing the G and A fragments) showed the 
clearest bands. 
1 2 3 
/ 5 5 
/ 2 2 
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Figure 19: An autoradiograph of the gel retention assay done 
with the lSOpb PCR product and nuclear proteins extracted 
using the Lee method. 
The first and last lanes represented the G and A fragment 
controls. Lanes 2, 4, 6 and a were the G fragments and lanes 
3, 5, 7 and 9 were the A fragments. Increasing amounts of 
poly d!dC were added with the least amount in lanes 2 and 3 
(2µg/µl) and the most in lanes 8 and 9 (8µg/µl) as indicated 
below the photograph. The DNA-protein complexes are 
represented by bands indicated as 1 to 9. 
4.2.3. COMPETITIVE GEL RETENTION ASSAYS: 
To determine the conditions for a competitive gel retention 
assay, an experiment was done to compete the non-radioactive 
G.-140.+10 fragment with radioactive G fragment, and the 
same was done with the A.-140.+10 fragment (method described 
in section 2.23}. Non-radioactive 150bp (-140.+10} fragments 
were purified using the PCR technique (as described in 
section 2.21), and were used in competitive studies with the 
radioactively labelled -140.+10 150bp fragments (figure 20). 
The control lanes (lanes 3 and 4), with no competitor, 
showed the same difference between the G and A fragment as 
observed in figure 19, namely the absence of band 3 in the 
lane with the A fragment. As the molar excess of the non-
radioactive fragment increased in lanes 5 and 6 to 9 and 10, 
the intensities of the bands, representing the DNA-protein 
complexes, decreased. At a 25 fold molar excess the effect 
of the competitor was obvious as all the DNA-protein 
complexes were uniformly competed out by the non-radioactive 
fragments. This implies that the non-radioactive fragment 
was competing for all the complexes that were formed between 
the proteins and the radioactive fragments (in both the G 
and the A fragments), and that the conditions were correct 
for the competitive gel retention assay. 
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Figure 20: An autoradiograph of a competition gel retention 
assay. 
The competition experiment was done with the non-radioactive 
G fragment competing with the radioactive G fragment for the 
protein complexes. Similar experiments were performed with 
the A fragment. Lanes 1 and 2 represent the controls. Lanes 
3 and 4 represent the G and A fragments incubated with 
nuclear proteins but no competitor. Lanes 5 and 6; 7 and 8 
represent the G and A fragments respectively (lane 9 = G 
fragment), with increasing molar excess of competitor from 
10 fold excess to 50 fold excess. 
Further competition studies were carried out to investigate 
whether the G and A fragments competed for the same protein 
complexes. 
A cross-competition gel retention assay was done by 
competing the radioactive G.-140.+10 fragment with non-
radioactive A.-140.+10 fragment and the radioactive 
A-140.+10 fragment with the non-radioactive G.-140.+10 
(figure 21). The original difference between the DNA-protein 
complexes in the G and A fragments was observed in lanes 3 
and 4 (no competitor). When the radioactive G fragment was 
completed with non-radioactive A fragment the relative 
intensities of bands 3 and 5 changed with the addition of 
the competitor (non-radioactive A fragment). Comparing lane 
3 with lanes 5, 7 and 9 as the molar excess of non-
radioactive A fragment increased, the intensity of band 3 
increased compared to the intensities of the other bands, 
while the intensity of band 5 decreased. This result implies 
that both the G and A fragments competed for complex 5, but 
the non-radioactive A fragment did not affect the binding of 
complex 3 (band 3) of the radioactive G fragment. This means 
that the band 3 represents a complex (complex 3) that only 
forms when the nuclear proteins are incubated with the G 
fragment and not with the A fragment. 
The results from the competition of the radioactive 
A.-140.+10 fragment with the non-radioactive G fragment 
competitor were slightly different, in that the intensity of 
all the DNA-protein complexes decreased with the increase in 
molar excess of the non-radioactive G fragment. The decrease 
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in intensity of the bands can be clearly seen in figure 21 
from the even numbered lanes 2 to 10. This result confirms 
the fact that the A fragment forms the same DNA-protein 
complexes as the G fragment, as the G fragment completes for 
all of the DNA-protein complexes formed by the A fragment. 
When the different autoradiographs (figures 19, 20, 21) were 
compared, it was noted that in figure 19 the A fragment 
forms complex 4. This complex was not observed in the other 
figures, probably because different batches of nuclear 
proteins were used. The nuclear proteins are susceptible to 
degradation during the isolation process and there was a 
batch to batch variation. Despite this variation as 
indicated in the gel retention autoradiographs, the G and A 
fragments consistently formed different complexes with 
nuclear proteins. 
Hence the results from the gel retention assays have shown 
that there is a DNA-protein binding difference between the G 
and the A fragments. This is thought to be due to the point 
mutation at the -76 position, as it was the only difference 
between the two DNA fragments (results not shown). 
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Figure 21: An autoradiograph of a cross-competition gel 
retention assay. 
This was done by using the non-radioactive G fragment to 
compete with the radioactive A fragment, and the radioactive 
G fragment was competed with the non-radioactive A fragment. 
The G and A fragment controls are represented in lanes 1 and 
2. Lanes 5, 7 and 9 represent the G fragment and lanes 6, 8 
and 10 represent the A fragment, with increasing excess 
amounts of non~radioactive competitor. (Note that lanes 6 
and 10 had less intense bands because the amount of nuclear 
proteins added was less than the other lanes). 
CHAPTER 5 
DISCUSSION 
It has been proposed that cholesterol transport via the 
reverse cholesterol transport pathway, involves the 
lipoprotein HDL. HDL sequests free cholesterol from the 
cells, esterifies it and delivers it to the liver. HDL and 
apoAI levels have been inversely correlated to coronary 
heart disease (9,10,11). The regulation of apoAI is, 
therefore, important in maintaining HDL levels and 
cholesterol homeostasis. The production of apoAI can be 
regulated by a variety of factors e.g. exercise, diet and 
hormones, with some of these regulatory factors affecting 
the level of DNA transcription of the apoAI gene. 
The promoter of the apoAI gene has been well characterized 
by DNAseI footprinting (60,61,62). Four DNAseI footprints 
have been observed (figure 3) in the -256 to +17 region, and 
proteins have been reported which bind to some of these 
sites. Three of the DNA-protein binding sites are present in 
the region -256 to -41 which has been shown to be important 
for HepG2 (liver) expression in vivo (64), as well as in 
transgenic mice (16). AG to A transitional point mutation 
was identified in the promoter region of the apoAI gene at 
position -76 (14). This mutation has been shown to 
contribute to the variance in the apoAI levels (76). The A 
allele has been associated with high apoAI levels in various 
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population studies (14,72,77,78). Contradicting results were 
reported by Smith, et al. (78) who showed that G/A 
heterozygous individuals had 11% lower apoAI production 
rates than the G homozygous individuals. However there was 
no effect on the HDL-cholesterol and apoAI levels in the 
group of individuals tested for this study. 
The significance of the point mutation was investigated with 
respect to its DNA-protein binding potential, and to its 
potential to affect the expression of the apoAI gene. The 
point mutation results in a direct 6bp repeat which abutts a 
DNAseI footprint (-128 to -77) (61). Hence the position of 
the mutation in the promoter region could alter apoAI gene 
expression. 
The -256 to +397 region of the apoAI promoter region was 
inserted upstream of the promoterless CAT gene. The 
A.-256.+397.p8CAT had a 1.91 fold increase in CAT expression 
when compared to G.-256.+397.p8CAT. These constructs 
contained the major DNA-protein binding regions (figure 14) 
i.e. the CAAT box, the TATA box and other areas that have 
been shown to be essential for promoter activity. 
The sequence of the G allele between +100 to +397 was not 
known, so this region was swopped with the equivalent region 
of the A fragment to abolish the effect of polymorphic 
differences between the G and the A fragments. The 
A.-256.+397.swop.p8CAT construct maintained a two fold 
increase in CAT expression when compared to the 
G.-256.+397.swop.p8CAT. This data could be interpreted to 
indicate that the 300bp fragment {+100 to +397) did not 
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alter the expression of the CAT gene as the CAT activity 
results from the 650bp and the swopped experiment was not 
significantly different (table 3). This means that even if 
there are any polymorphic differences between the two 300bp 
fragments (i.e. +100 to +397 in the G or A alleles}, these 
differences do not alter the transcription of the apoAI 
gene. Hence, the point mutation A at -76 causes an enhanced 
effect on the transcription when assayed in the -
256.+397.pSCAT construct irrespective of any possible 
polymorphic differences there might be between the 3' 
regions +100 to +397. 
To determine whether the point mutation at A-76 was 
sufficient for the expression of the apoAI promoter, the -
133 to +397 (-133.+397.pSCAT} construct was assayed for CAT 
activity. Widom and coworkers (60} had assayed the G.-
133.+397.RSVCAT and found that the relative CAT activity was 
120 fold less compared to the G.-256.+397.RSVCAT. This CAT 
activity was very low, and from this result they deduced 
that the regions upstream of the -133 were important in the 
expression of the apoAI promoter. The results obtained from 
this study supported their postulate, as the CAT activities 
were very low, at about 14 fold less than the -256.+397 
construct. This difference in CAT activity was not as 
dramatic as Widom, et al. (60} observed (they observed an 
effective 120 fold difference). This was possibibly due to 
the fact that they used a different CAT system in which the 
CAT gene was under the basal expression of the SV40 early 
promoter. The SV40 early promoter is a stronger promoter and 
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hence the promoter differences between a strong promoter 
(-256 to +397) and a weak promoter (-133 to +397) of the 
apoAI promoter are increased. A more sensitive assaying 
system would have to be used to determine if there is a 
difference between the G and A alleles when the -133.+397 
fragment is assayed. However, it can be postulated that the 
point mutation, or the region surrounding the point mutation 
has a modulating role in the expression of the apoAI 
promoter as it does not directly effect the expression of 
the apoAI promoter. This indicates that the apoAI promoter 
requires the presence of the upstream regions for efficient 
transcription. 
The possibility of the -76 position interacting with 
downstream elements in the +68 (StuI) to +397 (HindIII) 
region was investigated by determining the activity of the 
-256.+68.p8CAT constructs. The activities of these 
constructs were also assayed by Smith and coworkers (78), 
and they found that the A.-256.+68 fragment had 68% of the 
CAT activity of the G.-256.+68 fragment i.e. the A fragment 
had less CAT activity than the G fragment. This finding was 
also observed by Tuteja, et al. (83) who assayed the 
promoter activity of the -330 to +1 fragment of the apoAI 
promoter and found that the construct with the G at -76 had 
a 2 fold greater CAT activity than the equivalent A 
fragment. The results obtained in this study differed from 
the above studies in that there was no significant 
difference in CAT activity found between the G and the A 
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constructs when the -256.+68.p8CAT was assayed. This 
conflicting data could possibly be attributed to the fact 
that different size constructs and cell types were used e.g. 
Tuteja, et al. (83) used the fragment -330 to +1 in Hep3B 
cell line. The confluency of the cells could have been 
different in the two studies, which could cause different 
cellular interactions. Tuteja, et al. (83) also did not use 
Bgal for correcting the DNA uptake in cells, they used slot 
blot analysis which could result in a different sensitivity 
compared to the Bgal technique. 
It is interesting to note that the results obtained from the 
Tuteja, et al. (83) did not agree with their population 
study results (72), and although the synthetic rate of the 
apoAI of the G allele was higher than the A allele reported 
in the study by Smith, et al. (78), there was no change in 
the levels of apoAI of the individuals. 
An interesting finding with respect to the -256.+68 
constructs was that the CAT activity was three fold higher 
than that of the G.-256.+397.p8CAT. This implies that the 
330bp, 3'of the stuI site, contains a possible repressor 
element(s), and the removal of this region (+68 to +397) 
causes the activity of the promoter (-256.+68} to increase. 
The repressor element(s) appears to be common in both the G 
and the A fragments, because when the +100.+397 (300bp) 
regions were swopped, the expressions of the -256.+397 
fragments were unaltered. The relative CAT activity of the G 
allele decreased from 3.6 (-256.+68.p8CAT} to 1 
95 
(-256.+397.p8CAT}, with the addition of 330bp (+68.+397). In 
contrast the relative CAT activity of the A construct 
decreased from 3.8 (-256.+68.p8CAT} to only 2 
(-256.+397.p8CAT}. 
The decrease of CAT activity in the presence of the region 
+68 to +397 could be explained by four possible models: 
1. The repressor element(s) in the 3' region (+100 to +397) 
could interact differently with the region surrounding the 
-76 position according to the G or A base pair at -76. 
2. There could be more than one element involved in the 
overall repression of the apoAI promoter in that a 
repressor(s) could repress the CAT activity of the 
constructs irrespective of which allele it is, but an 
activator(s) that specifically recognizes the A allele 
activates the A alleles' expression. There are a number of 
combinations of activators and repressors that could cause 
an overall repression of the promoter. 
3. The A at -76 could be altering the conformation of the 
DNA and hence the element(s) downstream interact differently 
to cause the observed increase in promoter activity. 
4. The distance of the promoter elements from the CAT gene 
could affect the activity, however this does not explain the 
differential activity of the G and A constructs. 
The element(s) in the 330bp (+68 to +397) fragment need to 
be clarified by cloning sequential deletions of the 330bp 
fragment and assaying for CAT activity. Gel retention and 
DNAse I footprint analysis will also help to clearly 
identify the element(s) within the 330bp +68.+397 fragment. 
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Our data would suggest that the promoter activity of these 
constructs e.g. -256.+397.pSCAT are highly dependent on the 
3 1 flanking sequences. Results obtained from the study by 
Tuteja, et al. (83) indicated that sequences 5 1 of the -76 
position were also important in promoting a difference 
between the G and the A alleles, as the A fragment -1469 to 
+397 showed a small increase in promoter activity relative 
to the G fragment of an equivalent size. 
Altered transcription activities of the G and A alleles 
could be due to a difference in DNA-protein binding in the 
promoter region of the apoAI gene. The -76 point mutation 
abutts a DNAseI protection site so there is a good 
possibility that the point mutation causes altered DNA-
protein binding. Gel retention assays revealed that the DNA-
protein binding pattern between the two fragments (G and A 
fragments) was altered. The G and A fragments bound to a 
number of protein complexes. The G fragment appears to have 
a high affinity for complexes 3 and 5, as the intesities of 
the bands 3 and 5 were greater than the intensities of the 
other bands. In contrast to this, the lanes on the gel in 
which the A fragment was used showed a strong band at band 
position 5, but no band at the band 3 position was observed. 
The A allele sometimes formed band 4, but this depended on 
the batch of nuclear proteins used. The binding patterns of 
the DNA-protein complexes of the G and A fragments were 
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clearly different when analysed using the gel retention 
technique. 
Cross-competition studies were done to determine if the G 
and A fragments competed with each other for the protein 
complexes. The results from these experiments indicated that 
the A fragment competed for all of the protein complexes 
bound to the G fragment except for complex 3, as the 
intensities of all the other bands decreased with increasing 
non-radioactive A fragment, except for the complex 
represented by band 3. In fact the relative intensity of 
band 3 increased compared to the other bands. This relative 
increase in intensity of band 3 could be due to the fact 
that more radioactive fragment became available with the 
increase of competitor. The "extra" radioactive G fragment 
would then bind to the complex 3 as it has a great affinity 
for this protein complex and also there was no competition 
by the A fragment. These results indicate that the G 
fragment shares all of its complexes with the A fragment, 
except for one complex, complex 3, which is unique to the G 
fragment. 
The G fragment seems to have altered the conformation of the 
DNA proximal to the -76 position which then causes a 
difference in DNA-protein interactions. 
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There are three possibilities that could explain this 
result: 
1. The G fragment actually recognizes a different protein 
that forms complex three, and this protein does not 
recognize the A fragment. 
2. The G fragment could bind a protein, that also binds the 
A fragment, but the DNA-protein complex could have a 
different secondary structure. Hence a different 
conformation occurs and this will cause the complex to move 
through the polyacrylamide gel with a different mobility. 
3. By the same reasoning, a protein could have two 
conformational states e.g. a phosphorylated and a non-
phosphorylated form. The change in DNA sequence could allow 
for another form of the protein to bind e.g. a 
phosphorylated form, which would change the mobility of the 
DNA-protein complex and lead to altered gel retention 
patterns. 
Hence, it would appear from the data, that the G to A point 
mutation functionally alters the transcriptional activity of 




The point mutation G to A has been shown to alter the DNA-
protein interactions as the G fragment -140 to +10 forms a 
unique DNA-protein complex that was not present in the gel 
retention assays of the A fragment -140 to +10. The mutation 
at -76 could alter the conformation of the DNA allowing for 
a protein complex to bind elsewhere on the DNA fragment, as 
DNAseI footprint studies did not report a DNAseI footprint 
over the -76 position (61). 
Altered DNA-protein complex interactions could alter the 
rate of transcription. The A at -76 seems to have altered 
the transcriptional activity of the apoAI promoter as the 
A.-256.+397.pSCAT showed greater promoter expression than 
the G.-256.+397.pSCAT in vivo. The regions from -256 to -133 
were found to be essential for the efficient transcription 
of the apoAI gene in both the G and A constructs and the 
region immediately adjacent the -76 position does not appear 
to have transcriptional activity. From these results it 
becomes clear that the G/A at -76 has only a secondary role 
in the regulation of the transcriptional expression of the 
apoAI gene. The difference between the G and A fragments was 
abolished when the -256.+68 constructs were assayed for CAT 
activity. This indicates that the 3' region (+68 to +397) 
seems to have elements that cause a reduction in the 
100 
101 
promoter expression, but interacts differently with the 
regions surrounding the -76 position promoting the 
difference between the two alleles. This 3' region contains 
the first intron and part of the second intron, which could 
contain the elements that interact with the -76 position. 
The point mutation at -76, appears to have functionally 
altered the promoter activity of the apoAI gene in the 
region -256 to +397. The altered promoter activity could 
explain the results found in population studies which showed 
an association between high apcAI levels and the A allele. 
Further experiments would need to identify the element(s) in 
the 3' region and also the position at which altered DNA-
protein binding takes place in the G and A fragments e.g 
DNAseI footprints. Transgenic mice could be used which 
contain the regions -1469 to +397 of the G or A alleles of 
the apoAI gene. This would determine the overall effect of 
the point mutation on the transcription of the apoAI gene in 
vivo. 
PREPARATION OF SOLUTIONS 
1. Loading Buffer: 
25mg bromophenol blue 
25mg xylene cyanol 
30% glycerol 
H20 to 10ml 
2. TBE ( lOX) : 
108g Tris 
55g Boric acid 
40ml 0.5 EDTA pH 8.0 
H20 to 11 
APPENDIX 
3. Crush-Soak-Solution: (Section 2.5) 
a.SM ammonium acetate 
O.OlM magnesium acetate 
0.001M EDTA pH 8.0 
4. TE (lX) (pH 7.4, 7.8, 8.0): 
lOmM Tris.HCl pH 7.4, 7.8, 8.0 
lmM EDTA pH 8.0 
5. L-broth (from section 2.9): 
lOg tryptone 
5g yeast extract 
5-lOg NaCl 
6. Agar (section 2.10): 
lOg tryptone 




7. Solution 1 (section 2.11): 
25mM Tris.HCL pH 8.0 
lOmM EDTA 
SOmM glucose 
8. Solution 2 (section 2.11): 
0.2M NaOH 
1% SDS 
(stable for 1-2 weeks) 
9. Solution 3 (section 2.11): 
3M potasium acetate pH 4.8 
(correct pH with HAc) 
10. Suspension buffer (section 2.13): 
25% sucrose 
50mM Tris.HCL pH 8.0 
11. Lysozyme buffer (section 2.13): 
Smg/ml lysozyme 
25% sucrose 
SOmM Tris.HCL pH 8.0 
(made up fresh) 
12. Lysis buffer (section 2.13): 
0.5% Triton X-100 
SOmM Tris pH 8.0 
6.25 mM EDTA 











14. Solution B (section 
440µ1 DNA (dissolved 
60µ1 2M CaCl2 
per dish 






16. TNE (section 2.16): 
lOmM Tris.HCL pH 8.0 
lrn.M EDTA pH 8.0 
100 mM NaCl 





2. 16) : 
in water) 
2.17): 
50rn.M B-mercaptoethanol (added fresh) 




19. Minimal essential medium (MEM) (section 2.19): 
20rn.M MEM Hepes pH 7.4 
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50mM OTT (added fresh) 
lmM sperrnadine 
lmM EOTA pH 8.0 
2.20): 
22. Oignarn buffer A (section 2.22a): 
lOmM Hepes pH 7.9 
1. 5mM MgCl2 
lOmM KCl 
0.5rnM OTT (added fresh) 
2 3. Oignarn buffer C (section 2.22a): 





0.5rnM PMSF (added fresh) 
0.5rnM OTT (added fresh) 
24. Oignarn buffer 0 (section 2.22a): 




0.5rnM PMSF (added fresh) 
0.5rnM OTT (added fresh) 
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25. Green buffer A (section 2.22b): 
lOmM Hepes pH 8.0 
1. 5mM MgCl2 
lOmM KCl 
lmM OTT (added fresh) 
lµg/ml Pepstatin (added fresh) 
lµg/ml Leupeptin (added fresh) 
26. Green buffer C (section 2.22b): 
20mM Hepes pH 8.0 
1. 5mM MgCl2 
25% glycerol 
420mM NaCl 
0.2mM EOTA pH 8.0 
lmM OTT (added fresh) 
0.5 PMSF (added fresh) 
lµg/ml Pepstatin (added fresh) 
lµg/ml Leupeptin (added fresh) 
27. Green buffer O (section 2.22b): 




0.2mM EOTA pH 8.0 
lmM OTT (added fresh) 
0.5mM PMSF (added fresh) 
lµg/ml Pepstatin (added fresh) 
lµg/ml Leupeptin (added fresh) 
Incubation buffer (section 2.23): 
(5X) 
lOOmM Hepes pH 7.9 
250mM KCl 
2.5mM OTT (added fresh) 
lmM EOTA 
5mM MgCl2 
20% FiColl 400 
106 
REFERENCES: 
1. Gordon, D.J., and Rifkind, B.M. (1989) High density 
lipoprotein - the clinical implications of recent 
studies. N.E.J.M. 321 :1311-1316 
2. Johnson, W.J., Mahlberg, F.H., Rothblat, G.H., and 
Phillips, M.C. (1991) Review: Cholesterol transport 
between cells and high-density lipoproteins. Biochirn. 
Biophys. Acta. 1085 :273-298 
107 
3. Cooper, A.D. {1985) Role of the liver in the degradation 
of lipoproteins. Gastroenterology 88 :192-205 
4. Scanu, A.M. (1986) Plasma lipoproteins: an overview. 
Biochemistry and Biology of Plasma Lipoproteins. edited 
by Scanu, A.M., and Spector, A.A. The Biochemistry of 
disease 11 : 1-10 
5. Hay, R., Driscoll, D., and Getz, G. (1986) Biochemistry 
and Biology of Plasma Lipoproteins. edited by Scanu, 
A.M., and Spector, A.A. The Biogenesis of lipoproteins. 
The Biochemistry of Disease 11 : 11-51 
6. Olivecrona, T., and Bengtsson-Oliver Olivecrona, G. 
(1990) Lipases involved in lipoprotein metabolism. 
Current Opinion in Lipidology 1 :166-121 
7. Gotto, A.M., Pownal, H.J., and Harvel, R.J. (1986) 
Introduction to the plasma lipoproteins. Methods. 
Enzyrnol. 128 :3-41 
8. Tall, A.R. (1990) Plasma high density lipoproteins -
metabolism and relationship to atherogenesis. J. Clin. 
Invest. 86 :379-384 
9. Woo, J., Lou, E., Lam, c.w., Kay, R., Teoh, R., Wong, 
H.Y., Prall, W.Y., Kreel, L., and Nicholls, M.G. (Feb 
1991) Hypertension, lipoprotein(a), and apolipoprotein 
A-I as risk factors for stroke in the Chinese. Stroke 
22 :203-208 
10. Miller, E.M. (1987) Associations of high-density 
lipoprotein subclasses and apolipoproteins with 
ischernic heart disease and coronary atherosclerosis. 
Arn. Heart J. 113 :589-597 
11. Wilson, P.W.F., Abbott, R.D., and Castelli, W.P. 
(Nov/Dec 1988) High density lipoprotein cholesterol and 
mortality - The Framingham heart study. 
Arteriosclerosis 8 :737-741 
108 
12. Buring, J.E., O'Connor, G.T., Goldhaber, s.z., Rosner, 
B., Herbert, P.N., Blum, C.B., Breslow, J.L., and 
Hennekens, C.H. (Jan 1992) Decreased HDL2 and HDL3 cholesterol, ApoA-I and ApoA-II, and increased risk of 
myocardial infarction. Circulation (UNITED STATES) 85 
:22-29 
13. Miller, N.E., Hammett, s., Saltiss, S., Roa, s., van 
Zelles, H., Coltant, T., and Lewis, B. (1981) Relation 
of angiographically defined coronary artery disease to 
plasma lipoprotein subfractions and apolipoproteins 282 
:1741-1744 
14. Jeenah, M., Kessling, A., Miller, N., and Humphries, S. 
(Jun 1990) G to A substitution in the promoter region 
of the apolipoprotein AI gene is associated with 
elevated serum apolipoprotein AI and high density 
lipoprotein cholesterol concentrations. Mol. Biol. Med. 
7 : 233-241 
15. Nicols, A.V. (1967) Human serum lipoproteins and their 
interrelationships. Adv. Biol. Med. Phys. 11 :110-158 
16. Breslow, J.L., Walsh, A., and Ito, I. (1989) ApoA-I gene 
expression in transgenic mice - effects on HDL levels. 
Elsevier Science Publishers B.V. (Biomedical Division) 
High density lipoproteins and atherosclerosis II. 
N.E.Miller: 133-120 
17. Moll, P.P., Sing, C.F., Williams, R.R., Mao, S.J.T., and 
Kottke, B.A. (1986) Am. J. Hum. Genet. 38 :361-372 
18. Hamsten, A., Iselius, L., Dahlen, G., and de Faire, U. 
(1986) Genetic and cultural inheritance of serum 
lipids, low and high density lipoprotein cholesterol 
and serum apolipoproteins A-I, A-II and B. 
Atherosclerosis. 60 :199-208 
19. Rubin, E.M., Krauss, R.M., Spangler, E.A., Verstuyft, 
J.G., and Clift, S.M. (Sept 19 1991) Inhibition of 
early atherogenesis in transgenic mice by human 
apolipoprotein AI. Nature 353 :265-267 
20. Ueno, s., Kobori, s., Ide, M., suzaki, K., Takeda, H., 
Horiuchi, s., and Shichiri M. (Nov-Dec 1991) A specific 
binding site for lipoproteins containing apolipoprotein 
A-I on human hepatoma cell line HepG2. Jpn. J. Med. 
(JAPAN) 30 :524-533 
21. Xu, Q. (Jun 1991) Characterization of the HDL receptor 
and its ligand in cultured smooth muscle cells isolated 
from rabbit aorta. Chung Kuo I Hsueh Ko Hsueh Yuan 
Hsueh Pao 13 : 161-167 
22. Morrison, J., Fidge, N.H., and Tozuka, M. (Oct 5 1991) 
Determination of the structural domain of ApoAI 
recognized by high density lipoprotein receptors. J. 
Biol. Chem. (USA) 266 : 18780-18785 
23. von Rodenberg, E., Heinen, S., Howel, K.E., Luley, C., 
Kubler, W., and Band, H.M. (Nov 5 1991) Cholesterol 
efflux from macrophages mediated by high-density 
lipoprotein subfractions, which differ principlly in 
apolipoprotein A-I and apolipoprotein A-II ratios. 
Biochim. Biophys. Acta. (NETHERLANDS) 1086 : 173-184 
109 
24. Graham, D.L., and Oram, J.F. (1987) Identification and 
characterization of a high density lipoprotein-binding 
protein in cell membranes by ligand blotting. J. Biol. 
Chem. 262 :7439-7442 
25. Openheimer, M.J., Oram, J.F., and Bierman, E.L. (1988) 
Up-regulation of high density lipoprotein-receptor 
activity by yinterferon associated with inhibition of 
cell proliferation. J. Biol. Chem. 263 :19318-19323 
26. Mahlberg, F.H., Glick, J.M., Lund-Katz, s., and 
Rothblat, G.H. (Oct 25 1991) Influences of 
apolipoprotein AI,AII and C's on the metabolism of 
membrane and lysosomal cholesterol in macrophages. J. 
Biol. Chem. 266 : 19930-19937 
27. Leblond, L., and Marcel, Y.L. (Apr 5 1991) The 
amphiphathic alpha-helical repeats of apolipoprotein A-
I are responsible for binding of high density 
lipoproteins to HepG2 cells. J. Biol. Chem. 266 :6058-
6067 
28. Segrest, J.P., DeLoof, H., Dohlman, J.G., Brouillette, 
C.G., and Anantharamaiah, G.M. (1990) Amphiphathic 
helix motif: classses and properties. Proteins 8 :103-
177 
29. Mendel, C.M., Kunitake, S.T., Kane, J.P., and Kempner, 
E.S. (1988) Radiation inactivation of binding sites for 
high density lipoproteins in human fibroblast 
membranes. J. Biol. Chem. 263 :1314-1319 
30. Colbeau, A., Nachbaur, J., and Vignais, P.M. (1971) 
Enzymatic characterization and lipid composition of rat 
liver subcellular membranes. Biochim. Biophys. Acta. 
249 :462-492 
31. Lang, L. (1991) Disposition of intracellular cholesterol 
in human fibroblasts. J. Lipid. Res. 32 :329-339 
32. Schroeder, F., Jeffersen, J.R., Kier, A.B., Knittel, J., 
Scallen, T.J., Wood, W.G., and Hapala, I. (1991) 
Membrane cholesterol dynamics: cholesterol domains and 
kinetic pools. Proc. Soc. Exp. Biol. Med. 195 :235-252 
110 
33. Hui, s.w. (1988} The spatial distribution of cholesterol 
in membranes. In Biology of Cholesterol. P.L. Yeagle, 
editor. CRC Press, Boca Ratan, FL :213-231 
34. Schmitz, G., Assmann, G., Robenet, H., and Brennhausen, 
B. (1985} Tangier disease: a disorder of intracellular 
membrane traffic. Proc. Natl. Acad. Sci. USA 82 :6305-
6309 
35. Takahashi, K., Fukuda, S., Naito, M., Horiuchi, s., 
Takata, K., and Morino, Y. (1989) Endocytic pathway of 
high density lipoproteins via trans-golgi system in rat 
resident peritoneal macrophages. Lab. Invest. 61 :270-
277 
36. Kambouris, A.M., Roach, P.D., and Calvert, G.D., and 
Nestel, P.J. (July/Aug 1990) Retroendocytosis of HDL by 
the human hepatoma cell line, HepG2. Arteriosclerosis 
10 :582-590 
37. Oram, J.F., Mendez, A.J., Slotte, J.P., and Johnson, 
T.F. (1991) High density lipoprotein apolipoprotein 
mediate removal of sterol from intracellular pools but 
not from plasma membranes of cholesterol-loaded 
fibroblasts. Arteriosclerosis and Thrombosis 11 :403-
414 
38. Rothblat, G.H., Mahlberg, F.H., Johnson, W.J., and 
Phillips, M.C. (1992) Apolipoproteins, membrane 
cholesterol domains, and the regulation of cholesterol 
efflux. J. Lipid. Res. 33 :1091-1097 
39. Subbaiah, P.V., Norum, R.A., and Bagdade, J.D. (Oct 
1991) Effect of apolipoprotein activators on the 
specificity of lecithin: cholesterol acyltransferase 
determination of cholesterol esters formed in A-I/C-III 
deficiency. J. Lipid. Res. (UNITED STATES) 32 :1601-
1609 
40. Pfeuffer, M.A., Richard, B.M., and Pittman, R.C. (1992} 
Probucol increases the selective uptake of HDL 
cholesterol esters by HepG2 human hepatoma cells. 
Arteriosclerosis and Thrombosis 12 :870-878 
41. Brewer, H.B. Jr, Fairwell, T., LaRue, A., Ronan, R., 
Houser, A., and Branzert, T.J. (1978} The amino acid 
sequence of human apoA-I, an apolipoprotein isolated 
from high density lipopoproteins. Biochem. Biophys. 
Res. Commun. 80 :623-630 
42. Karathanasis, S.K. (Oct 1985) Apolipoprotein multigene 
family: tandem organization of human apolipoprotein AI, 
CIII, AIV genes. Proc. Natl. Acad. Sci. USA 82 :6374-
6378 
111 
43. Cheung, P., Kao, F-T., Law, M.L., Jones, c., Puck, T.T., 
and Chan, L. (Jan 1984) Localization of the structural 
gene for human apolipoprotein A-I on the long arm of 
human chromosome 11. Proc. Natl. Acad. Sci. USA 81 
:508-511 
44. Boguski, M.S., Elshourbagy, N., Taylor, J.M., and 
Gordon, J.I. (Feb 1985) Comparative analysis of 
repeated sequences in rat apolipoproteins A-I, A-I, and 
E. Proc. Natl. Acad. Sci. USA 82 :992-996 
45. McLachlan, A.D. (1977) Repeated helical pattern in 
apolipoprotein-A-I. Nature. (London) 267 :465-466 
46. Laman-Fava, s., Sastry, R., Ferrari, s., Rajavashisth, 
T.B., Lusis, A.J., and Karathanasis, S.K. (1992) 
Evolutionary distinct mechanisms regulate 
apolipoprotein A-I gene expression: differences between 
avian and mammalian apoA-I gene transcription control 
regions. J. Lipid. Res. 33 :831-842 
47. Williams, P.T., Wood, P.D., Haskell, W.L., and Vranizan, 
K. (May 21 1982) The effects of running mileage and 
duration on plasma lipoprotein levels. J.A.M.A. 247 
:2674-2679 
48. Wood, P.D., Haskell, W.L., Blair, S.N., Williams. P.T., 
Kraus, R.M., Lindgren, F.T., Albers, J.J., Ho, P.H., 
and Farquhar, J.W. (1983) Increased exercise level and 
plasma lipoprotein concentration: a one year, 
randomized, controlled study in sedentary, middle-aged 
men. Metabolism 32 :31-39 
49. Wood, P.D., Stefanick, M.L., Drean, D.M., Frey-Hewitt, 
B., Garay, s.c., Williams, P.T., Superko, H.R., 
Fortmann, S.P., Albers, J.J., Vranizan, K.M., 
Ellsworth, N.M., Terry, R.B., and Haskell, W.L. (Nov 3 
1988) Changes in plasma lipids and lipoproteins in 
overweight men during weight loss through dieting as 
compared with exercise. N.E.J.M. 319 :1173-1179 
50. Tikkanen, H.O., Harkonen, M., Naveri, H., Hamalainen, 
E., Elovainio, R., Sarna, S., and Frick, M.H. (Sep 
1991) Relationship of skeletal muscle fibre type to 
serum high density lipoprotein cholesterol and 
apolipoprotein A-I levels. Atherosclerosis (IRELAND) 90 
:49-57 
51. Osada, J., Fernandez-Sanchez, A., Diaz-Morillo, J.L., 
Aylages, H., Miro-Obradors, M.J., Ordovas, J.M., and 
Palacios-Alaiz, E. (Oct 15 1991) Hepatic expression of 
apolipoprotein A-I gene in rats is upregulated by 
monosaturated fatty acid diet. Biocem. Biophys. Res. 
Commun. (UNITED STATES) 180 : 162-168 
52. Srivastava, R.A.K., Tango, J., Pfleger, B., Kitchens, 
T., and Schonfeld, G. (Sep/Oct 1991) Differential 
regulation of apolipoprotein A-I gene expression by 
dietary fat and dietary cholesterol in inbred strains 
of mice. Arteriosclerosis Council of Abstracts. 
Arteriosclerosis and Thrombosis 11 :1446a 
112 
53. Patsh, J.R., Prasad, s., Gotto, A.M. Jr, and Patsch, W. 
(1987) High density lipoprotein 2: relationship of the 
plasma levels of this lipoprotein species to its 
composition, to the magnitude of postprandial lipemia, 
and to the activities of lipoprotein lipase and hepatic 
lipase. J. Clin. Invest. 80 :341-347 
54. Hennessy, L.K., Osada,J., Ordovas, J.M., Nicolosi, R.J., 
Stucchi, A.F., Brousseau, M.E., and Schaefer, E.J. (Mar 
1992) Effects of dietary fats and cholesterol on liver 
lipid content and hepatic apolipoportein A-I, Band E 
and LDL receptor mRNA levels in cebus monkeys. J. 
Lipid. Res. (UNITED STATES) 33 :351-360 
55. Walsh, B.W., and Sacks, F.M. (Sep/Oct 1991) Estrogen 
treatment raises plasma HDL concentrations by 
increasing HDL production. Arteriosclerosis Council of 
Abstracts. Arteriosclerosis and Thrombosis 11 :1400a 
56. Kushwaha, R.S., Foster, D.M., Murthy, V.N., Carey, K.D., 
and Bernard, M.G. (May 1990) Metabolic regulation of 
apoproteins of high density lipoproteins by estrogen 
and progesterone in the baboon. Metabolism 39 :544-552 
57. Tang, J.J., Krul, E.S., and Schonfeld, G. (Dec 31 1991) 
In vivo regulation of apolipoprotein AI gene expression 
by estradiol and testosterone occurs at the 
translational level in inbred strains of mice. Biochem. 
Biophys. Res. Commun. (UNITED STATES) 181 :1407-1411 
58. Strobl, w., Gorder, N.L., Lin-Lee, Y.C., Grotto A.M. Jr, 
and Patsch, W. (Mar 1990) Role of thyroid hormones in 
apolipoprotein A-I gene expression in rat liver. J. 
Clin. Invest. 85 :659-667 
59. Davidson, N.O., Carlos, R.C., Drewek, M.J., and Parmer, 
T.G. (1988) Apolipoprotein gene expression in the rat 
is regulated in a tissue-specific manner by thyroid 
hormone. J. Lipid. Res. 29 :1511-1522 
60. Widom, R.L., Ladias, J.A., Kouidou, S., and 
Karathanasis, S.K. (Feb 1991) Synergistic interactions 
between transcription factors control expression of the 
apolipoprotein AI gene in liver cells. Mol. Cell. Biol. 
11 : 677-687 
113 
61. Papazafiri, P., Ogami, K., Ramji, D.P., Nicosia, A., 
Monaci, P., Cladoras, c., and Zannis, V.I. (Mar 25 
1991) Promoter elements and factors involved in hepatic 
transcription of the human ApoA-I gene positive and 
negative regulators bind to overlapping sites. J. Biol. 
Chem. 266 :5790-5797 
62. Ladias, J.A., and Karathanasis, S.K. {Feb 1 1991) 
Regulation of the apolipoprotein AI gene by ARP-1, a 
novel member of the steroid receptor superfamily. 
Science. 251 :561-265 
63. Rottman, J.N., Widom, R.L., Nada-Ginard, B., Mahdavi, 
V., and Karathanasis, S.K. (July 1991) A retinoic acid-
responsive element in the apolipoprotein AI gene 
distinguishes between two different retinoic acid 
response pathways. Mol. Cell. Biol. 11 :3814-3820 
64. Sastry, K.N., Seedorf, u., and Karathanasis, S.K. (Feb 
1988) Different cis-acting DNA elements control 
expression of the human apolipoprotein AI gene in 
different cell types. Mol. Cell. Biol. 8 :605-614 
65. Higuchi, K., Law, s.w., Hoeg, J.M., Schumacher, U.K., 
Meglin, N., and Brewer, H.B. Jr. (Dec 5 1988) Tissue-
specific expression of apolipoprotein A-I (ApoA-I) is 
regulated by the 5'-flanking region of the human ApoA-I 
gene. J. Biol. Chem. 263 :18530-18536 
66. Ruiz-Opazo, N., and Zannis, V.I. (Feb 5 1988) Expression 
of the human apolipoprotein A-I gene in rat myogenic 
L6E9 cells. J. Biol. Chem. 263 :1739-1744 
67. Shemer, R., Walsh, A., Eisenberg, S., Breslow, J.L., and 
Razin, A. (Jan 15 1990) Tissue-specific methylation 
patterns and expression of the human apolipoprotein AI 
gene. J. Biol. Chem. 256 :1010-1015 
68. Schemer, R., Kafri, T., O'Connell, A., Eisenberg, s., 
Breslow, J.L., and Razin, A. (Dec 15 1991) Methylation 
changes in the apolipoprotein AI gene during embryonic 
development of the mouse. Proc. Natl. Acad. Sci. USA 
{UNITED STATES) 88 :11300-11304 
69. Shemer, R., Eisenberg, S., Breslow, J.L., and Razin, A. 
(Dec 15 1991) Methylation patterns of the human apoA-
I/C-III/A-IV gene cluster in adult and embryonic 
tissues suggest dynamic changes in methylation during 
development. J. Biol. Chem. 266 :23676-23681 
70. Haase, A., and Stoffel, W. (April 1990) The 3 1 -flanking 
region shared by the human apolipoprotein AI and CIII 
gene regulates gene expression in cooperation with 5'-
flanking elements. Biol. Chem. {Hopper-Seyler) 371 
:375-382 
114 
71. Mietus-Snyder, M., Sladek, F.M., Ginsburg, G.S., Kuo, 
C.F., Ladias, J.A., Darnell, J.E. Jr, and Karathanasis, 
S.K. (Apr 1992) Antagonism between apoliprotein AI 
regulatory protein 1, Ear3/COUP-TF, and hepatocyte 
nuclear factor 4 modulates apolipoprotein CIII gene 
expression in liver and intestinal cells. Mol. Cell. 
Biol. (UNITED STATES) 12 :1708-1718 
72. Pagani, F., Sidoli, A., Giudici, G.A., Barenghi, L., 
Vergani, c., and Baralle, F. (1990) Human 
apolipoprotein A-I gene promoter polymorphism: 
association with hyperalphalipoproteinernia. J. Lipid. 
Res. 31 :1371-1377 
73. Xu, C.F., Nanjee, M.N., Savill, J., Talmud, P.J., 
Angelico, F., Del Ben, M. Antonini, R., Mazzarella, B., 
Miller, N., and Humphries, S.E. (Sep 1990) Variation at 
the apolipoprotein (apo) AI-CIII-AIV gene cluster and 
apoB gene loci is associated with lipoprotein and 
apolipoprotein levels in Italian children. Arn. J. Hurn. 
Genet. 47 :429-439 
74. Kessling, A.M., Horsthernke, B., and Humphries, S.E. 
(1985) A study of DNA polymorphisms around the human 
apolipoprotein AI gene in hyperlipidaernic and normal 
individuals. Clin. Genet. 28 :296-306 
75. Kessling, A., Rajput-Williarns, J., Bainton, D., Scott, 
J., Miller, N.E., Baker, I., and Humphries, S.E. (1988) 
DNA polymorphisms of the apolipoprotein AII and AI-
CIII-AIV genes: a study in men selected for differences 
in high density lipoprotein cholesterol concentration. 
Arn. J. Hurn. Genet. 42 :458-467 
76. Humphries, S.E. (1988) DNA polymorphisms of the 
apolipoprotein genes - their use in the investigation 
of the genetic component of hyperlipidaernia and 
atherosclerosis. Atherosclerosis 72 :89-108 
77. Paul-Hayase, H., Rosseneu, M., Robinson, D., van 
Bervliet, J.P., Deslypere, J.P., and Humphries, S.E. 
(Feb 1992) Polymorphisms in the apolipoprotein (apo) 
AI-CIII-AIV gene cluster: detection of genetic 
variation determining plasma apoAI, apoCIII and apoAIV 
concentrations. Hurn. Genet. (GERMANY) 88 :439-446 
78. Smith, J.D., Brinton, E.A., and Breslow, J.L. (1992) 
Polymorphism in the human apolipoprotein A-I gene 
promoter region. J. Clin. Invest. 89 :1796-1800 
79. Lowry, O.H., Rosebrough, N.J., Farr, A.L., and Randall, 
R.L. (1951) Protein measurement with the folin phenol 
reagent. J. Biol. Chern. 193 :265-275 
115 
80. Gorman, C.M., Moffat, L.F., and Howard, B.H. (1982) 
Recombinant genomes which express chloramphenicol 
acetyltransferase in mammalian cells. Mol. Cell. Biol. 
2 :1044-1051 
81. Dignam, J.D., Lebovitz, R.M., and Roeder, R.G. (1983) 
Accurate transcription initiation by RNA polymerase II 
in a soluble extract from isolated mammalian nuclei. 
Nucleic. Acids. Res. 11 :1475-1489 
82. Lee, K.A.W., and Green, M.R. (1990) Small scale 
preparation of extracts from radiolabeled cells 
efficient in pre-mRNA splicing. Methods. Enzymol. 181 
:20-30 
83. Tuteja, R., Tuteja, N., Melo, C., Casari, G., and 
Baralle, F.E. (1992) Transcription efficiency of human 
apolipoprotein A-I promoter varies with naturally 
occuring A to G transition. FEBS Letters. 304 :98-101 
